Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 19, 2026.

Blood-Brain Barrier Disruption by Lipopolysaccharide and Sepsis-Associated Encephalopathy

Xiaoyao Peng, Zhixuan Luo, Shuang He and 2 more

Frontiers in Cellular and Infection Microbiology · 2021 · Review · CC BY

doi:10.3389/fcimb.2021.768108

Abstract

As a complex multicellular structure of the vascular system at the central nervous system (CNS), the blood-brain barrier (BBB) separates the CNS from the system circulation and regulates the influx and efflux of substances to maintain the steady-state environment of the CNS. Lipopolysaccharide (LPS), the cell wall component of Gram-negative bacteria, can damage the barrier function of BBB and further promote the occurrence and development of sepsis-associated encephalopathy (SAE). Here, we conduct a literature review of the direct and indirect damage mechanisms of LPS to BBB and the relationship between these processes and SAE. We believe that after LPS destroys BBB, a large number of inflammatory factors and neurotoxins will enter and damage the brain tissue, which will activate brain immune cells to mediate inflammatory response and in turn further destroys BBB. This vicious circle will ultimately lead to the progression of SAE. Finally, we present a succinct overview of the treatment of SAE by restoring the BBB barrier function and summarize novel opportunities in controlling the progression of SAE by targeting the BBB.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

All organisms with a well-developed central nervous system (CNS) have a blood-brain barrier (BBB). The CNS has always been in a dynamic equilibrium environment that is significantly different from the peripheral environment and this is mainly determined by the barrier function of the BBB. The BBB is mainly composed of vascular endothelial cells (ECs) and basement membrane (BM), and there are also pericytes and astrocyte end-feet covering them, which together constitute the neurovascular unit (NVU) to maintain the function of BBB.

In addition, neurons and microglial cells, as components of the NVU, can also directly or indirectly affect the development and functions of the BBB. As a protective barrier at the interface of the brain and the peripheral environment, BBB successfully shields the CNS from toxic substances circulating in the blood by strictly controlling the material exchange between blood and brain tissue. And, as a dynamic interface, BBB’s structure is often damaged in pathological conditions, leading to the disruption of barrier function, which is mainly manifested in the increased permeability of both transcellular and paracellular pathways. Lipopolysaccharide (LPS), also known as endotoxin, which is the cell wall component of Gram-negative bacteria, is the main cause of sepsis. Purified LPS is widely used to construct pathological models of sepsis and its complications. Intensive researches have demonstrated that LPS could destroy the BBB through a variety of mechanisms, and the damaged BBB would promote the development of multiple brain diseases, including the sepsis-associated encephalopathy (SAE). In recent years, SAE caused by the disrupted BBB has attracted extensive attention, in which a CNS often has no obvious infection, but patients have significant cognitive dysfunction, memory decline, and other symptoms of serious complications.

In view of the fact that LPS can damage the BBB to cause serious diseases, here we review the relevant literature in recent years to elaborate the specific mechanism of LPS on BBB damage from two aspects of direct and indirect effects, and to discuss the links between BBB damaging by LPS and SAE, and the possible means to treat SAE by targeting the BBB.

Paracellular Pathways

Controlling substances and cells into and out of CNS is the most important function of BBB, especially preventing toxins and pathogens from entering the brain. It guarantees the relative stability of CNS under different conditions, which is conferred by the low permeability of transcellular pathway and paracellular pathway of BBB. The low permeability of paracellular pathways is mainly determined by tight junctions (TJs), which mainly consist of densely distributed transmembrane protein claudin (especially claudin-5), occluding, tricellulins, junctional adhesion molecules, and intracellular support proteins such as zona occludens (ZO). TJs are mostly located between brain ECs, sealing the paracellular pathway of molecules, greatly reducing the permeation of polar solutes from plasma to extracellular fluid of the brain, which play an important role in maintaining the integrity of BBB. In addition, adherens junctions (AJs) formed by intercellular cadherin (e.g., vascular-endothelial (VE-) cadherin) and intracellular catenin (e.g., epithelial (E-)cadherin), which connect cells together, are the basis of TJs and are also involved in maintaining the barrier function of BBB.

LPS has been demonstrated in several studies to enhance BBB permeability by killing TJs and AJs, decreasing their expression, and altering their distribution, allowing hazardous chemicals to pass across the BBB and induce CNS dysfunction. Seok et al. have confirmed that LPS can reduce the amount of TJs proteins, ZO-1 and claudin-5, and change their cellular localization by transferring them from the cell membrane to the cytoplasm after 14 days’ treatment. LPS produced by Bacteroides fragilis has been found to damage the BBB by disrupting intercellular adhesion proteins and cleaving cadherin. Besides, LPS of Escherichia coli O111:B4 treatment directly cause the formation of the paracellular gap by increasing the expression of C-X-C Motif Chemokine Receptor 2 (CXCR2) on brain ECs in a time-dependent manner (4-24 h post LPS injection), which was involved in endothelial actin polymerization and actin stress fiber formation. Another important factor involved in LPS-mediated damage to TJs is matrix metalloproteinase (MMP), especially MMP-9, which participates in the degradation of TJs and thereby elevates BBB permeability. MMP is regulated by a variety of cytokines on the mitogen-activated protein kinase (MAPK) pathway without overexpression in normal brain tissues. Qin et al. found that LPS could increase phosphorylation of p38MAPK and inhibition of p38MAPK could significantly inhibit LPS-induced MMP-2 overexpression at both the mRNA and protein levels, thereby attenuating the effect of LPS on occluding (Figure 1). It is worth mentioning that c-Jun amino-terminal kinase (JNK) in the MAPK family plays a similar function to p38MAPK. This suggests that the MAPK family may be involved in the process that LPS disrupts TJs.

Nuclear factor-k-gene binding (NF-κB) is a key regulator of inflammation-related gene expression in human cells, and LPS can stimulate NF-κB expression by binding to Toll-like receptor 4 (TLR4).. Hu et al. found that LPS can destroy BBB by reducing the level of occludin through TLR4/NF-κB pathway. Ras homolog family member A(RHOA), which induces intracellular inflammatory signal transduction and acts as a regulator of the integrity of intercellular junctions, has been found to be involved in promoting disassembly of TJs. Studies have found that LPS of E. coli O55:B5 can activate RHOA as well as downstream NF-κB, and lead to increased phosphorylation of myosin light chain (MLC), which ultimately causes a decrease in the expression of TJs proteins, claudin-5 and ZO-1 (Figure 1). In addition, studies found that the NF-κβ/cyclooxygenase-2 (Cox-2) pathway is involved in the process of BBB damage by LPS of E. coli O111:B4, and inhibition of Cox-2 prevented the LPS-induced decrease in Transendothelial electrical resistance (TEER) and improved the amount of ZO-1, showing a decrease in BBB permeability (Figure 1). Therefore, NF-κB and its associated molecules play an important role in the process of TJs damage in inflammatory responses mediated by LPS, ultimately disrupting BBB function.

Oxidative stress, which is mainly manifested by excessive production of reactive oxygen species (ROS), occurs widely when the balance between oxidation and antioxidation is broken. Treatment of human brain microvascular endothelial cells (BMECs) with LPS of E. coli O111:B4 leads to an abnormal increase in ROS, which further caused a significant decrease in occludin and claudin-5 after 8 hours’ treatment, and a time-dependent decrease in TEER, indicating the damage of BBB. In addition to causing direct damage to TJs, ROS induced by LPS of E. coli O111:B4 can also activate other molecular pathways such as RHOA/phosphoinositide 3-kinase (PI3K)/protein kinase B(AKT) to reduce the expression of occludin and claudin-5, and cause the reduction of TEER. Studies have proved that the phosphorylation of MAPK can be inhibited when the ROS production induced by LPS of E. coli O111:B4 is inhibited, thus decreasing the phosphorylation of TJs and protecting the integrity of BBB. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is an important source of ROS and is demonstrated to participate in the process of BBB dysfunction. In the study of Zhao et al., LPS of E. coli O111:B4 treatment increased the activity of NADPH oxidase (NOX) in a time-dependent manner (0-24 hours post LPS treatment), and the accumulation of ROS induced by LPS was significantly reduced after inhibiting the activity of NOX. Exogenous antioxidants such as Superoxide Dismutase(SOD) and 4,4’-Diaminodiphenylsulfone, Dapsone (DDS) were found to reduce the damage of LPS to BBB by preventing LPS-induced ROS accumulation, thereby restoring the expression of TJ proteins to maintain the low permeability of BBB.In view of this, activating endogenous antioxidant molecules inhibited by LPS may be a better solution to attenuate the damage of LPS to BBB. As a transcription factor that regulates the expression of multiple antioxidant genes, Nuclear factor-erythroid 2-related factor 2 (Nrf2) deficiency was found to cause an increase in intracellular ROS levels. Li et al. found that LPS treatment led to an increase production of ROS in both in vivo and in vitro experiments by inhibiting the expression of Nrf2, which was accompanied by decreased TEER and ZO-1, two indicators for a breakdown of the BBB (Figure 1). After artificially silencing the expression of Nrf2, a significant increase in ROS related to the enhanced expression of NOX1 can be observed, and this effect was amplified by the presence of LPS (Figure 1). Researchers have attempted to activate AMPK in both genetic and non-genetic ways since long-term exposure to E. coli O111:B4 LPS was shown to cause a reduction in its activity. The results showed that activation of AMPK significantly reduced LPS-induced NOX and ROS production after 24 hours’ treatment, ultimately improving the expression of occludin and claudin-5. Activating AMPK with metformin by Takata et al. showed reduced permeability of BBB, which manifests itself specifically as an increase in TEER and a decrease in Evans blue albumin permeability. Therefore, LPS can dysregulate the oxidative and antioxidant responses in ECs by inducing the expression of ROS, which ultimately leads to damage of TJs and disruption of BBB.

As a cysteine rich acidic secreted protein, secreted protein acidic and rich in cysteine (SPARC) is highly expressed not only at the early stage of cerebrovascular development, but also at sites such as injury and tumors, and it is related to the angiogenesis and the integrity of BBB. Addition of exogenous LPS caused an increase in SPARC, which in turn led to a decrease in the expression of ZO-1 and occluding, and finally a rise in BBB permeability at 24 h in a concentration-dependent manner. Researchers believe that SPARC’s primary function after stimulated by LPS is to promote ECs proliferation at the damaged site and to protect BBB, but SPARC also reduces the expression of ZO-1 and occluding, and eventually increases BBB permeability (Figure 1).

Transcellular Pathway

Concerning the transcellular transport of substances by the BBB, it is generally accepted that there are four pathways to transport ions and molecules between the blood and the brain: i) Free diffusion of lipid-soluble substances and gas small molecules; ii) polar molecules that cannot diffuse freely are transported by solute carriers; iii) A variety of lipid-soluble substances can be selectively transported by ATP-binding cassette transporters (ABCs); iv) Vesicular transport of macromolecules, also known as transcytosis. Notably, vesicular transport in ECs at the BBB was slower than that in most peripheral ECs, which may be due to inhibition of caveolae-mediated transcytosis. Since the first two pathways is mainly related to the concentration difference of intracellular and extracellular solutes rather than a regulatory role of the cell itself, the low permeability of BBB is achieved primarily by the efflux effects of ABCs and the inefficient vesicle transport.

P-glycoprotein (P-gp), an important efflux transporter belonging to ABCs. Reduced expression and activity of P-gp may cause an accumulation of toxic metabolites in the CNS, leading to an increased risk of cerebral diseases. Studies showed that LPS of E. coli O111:B4 can disrupt BBB permeability by affecting the activity of P-gp, causing various neurotoxins and pathogenic microorganisms to fail to drain out of the brain. In the study of Hartz et al., [N-ϵ(4-nitrobenzofurazan-7-yl)-d-Lys8]-cyclosporin A, a substance that accurately and specifically reflects the activity of P-gp in the vascular lumen, was declined in a concentration-dependent way after brain capillaries were treated with LPS, indicating a decrease in the activity of P-gp upon LPS treatment. Further studies showed that LPS activates molecules such as tumor necrosis factor-α (TNF-α), endothelin (ET)-1 by binding to TLR4 on the EC membrane, which ultimately causes a rapid and reversible decline in P-gp activity (Figure 1). In the study of Salkeni et al., they excluded the roles of blood circulating factors in the actions of LPS of Salmonella typhimurium on the activity of P-gp by intraperitoneal perfusion of CD-1 mice, and their results also showed that LPS inhibited the activity of P-gp independent of prostaglandins or nitric oxide (NO). It is worth noting that LPS reduced P-gp activity by directly activating nitric oxide synthase (NOS) by Hartz et al., which is inconsistent with the study by Salkeni et al., and the possible reason may be due to the involvement of microglia in the latter study. Pan et al. showed that LPS of S. typhimurium regulated NF-κB to elevate P-gp expression after 48 hours’ treatment, while the efflux activity of P-gp decreased, so the regulation of P-gp by LPS was most likely to be achieved by post-translational modifications.

In addition to ABCs, caveolae-associated transcytosis also plays an important role in maintaining low permeability in the transcellular pathway of the BBB. Caveolin-1 (cav-1) is a major component of caveolae and its expression level or activity would have a significant impact on transcellular permeability. Wang et al. found that LPS had no obvious effect on the expression of cav-1, but would increase the phosphorylation degree of cav-1 after treatment for 4 and 24 hours, and inhibition of cav-1 phosphorylation with drugs was accompanied by a decrease in BBB permeability (Figure 1). Increased phosphorylation of cav-1upon LPS treatment may have led to structural changes of caveolae, ultimately elevating the permeability of BBB. Collectively, LPS affects the permeability of the BBB transcellular pathway mainly through regulating of P-gp and cav-1.

Endothelial Cells

Vascular ECs constitute the main cellular components of the BBB, and structural damage to the endothelium or a decrease in the number of ECs may elevate the permeability of the BBB. Studies showed that the apoptosis of ECs is closely related to BBB damage and cerebral microcirculation disturbance, so the effect of LPS on the apoptosis of ECs of BBB may refine the mechanism of damage to the BBB by LPS. Cardoso et al. found that LPS of E. coli O111:B4 treatment causes time-dependent apoptosis of mouse BMECs. A similar result was also reported by Li et al., who found that LPS could increase the apoptosis of bend.3 cells and decrease their activity after 24 hours’ treatment. To further clarify the underlying mechanism of cell apoptosis induced by LPS, apoptosis analysis of human microvascular endothelial cell(HCMEC/D3) treated by LPS was performed by Liu et al. They showed that as the concentration of LPS increased, the activity of Caspase3/7 rose, the expression of the pro-oncogene Bax increased and the tumor suppressor gene Bcl-2 decreased (Figure 1). They further found that the effects of LPS on HCMECs could be reversed by enhancing the expression of endothelial nitric oxide synthase (eNOS) and Guanosine triphosphate cyclohydrolase 1 (GTPCH1), two proteins that are involved in ECs protection, indicating that LPS may damage the function of BBB by promoting EC apoptosis via inhibiting eNOS and GTPCH1 (Figure 1). In addition, Boitsova et al. found that the expression of Ki-67 protein, which is associated with cell proliferation, significantly decreased in rat BMECs after treated the LPS of E. coli O111:B4 for 72 hours (Figure 1). These results indicated that LPS can promote apoptosis and reduce the proliferation of EC, and ultimately destroy the structure and disrupt the function of BBB.

Mitochondria are the center of cellular energy metabolism. Abnormal energy metabolism of mitochondria in ECs of the BBB is usually followed by bioenergetics disruption of ECs, which may finally cause the BBB dysfunction. Haileselassie et al. found that mitochondrial damage in ECs and subsequent disruption of the BBB were caused by reduced mitochondrial membrane potential and increased oxidative stress after LPS treatment. They also showed that the permeability of microvascular ECs/astrocytes co-culture system increased upon LPS treatment for 24 hours, and this phenomenon resulted from pathological activation of dynamin-related protein-1 (Drp1)(Figure 1). Inhibition of Drp1 with P110, an inhibitor of Drp1- Fission 1 (Fis1) interaction, was found to attenuate LPS induced oxidative stress as well as elevate the membrane potential of mitochondria, which consequently improved the integrity of BBB. Besides, the injection of LPS resulted in a decline in the mitochondrial ATP as well as a rise in ROS levels in the brain, which might be attributed to LPS of E. coli O55:B5 interfering with mitochondrial transcription as well as oxidative phosphorylation. Monocarboxylate transporter-1 (MCT-1), as a lactate receptor expressed at luminal and abluminal membranes, carries on the influx and efflux of lactate between cells and contributes to the effective metabolic coupling of NVU cells. Boitsova et al. found that LPS of E. coli O111:B4 treatment inhibited the expression of MCT-1 in BMECs after 24 hours’ treatment, which consequently leads to insufficient uptake of lactate by cells (Figure 1). Thereby, the mitochondrial dynamic effects mediated by lactate are later suppressed, and then the metabolic state of mitochondria, especially energy production, was disrupted. As lactate transport is closely associated with proliferation activity of BMECs and highly selected permeability of the BBB, it was found that cell proliferation activity decreased while BBB barrier function was impaired in the presence of LPS.

To explore the roles of LPS in oxidative phosphorylation and mitochondrial volume in ECs, cultured cerebrovascular endothelial cells (cCVECs) were used as an in vitro BBB model by. They found that the expression of myeloid differentiation factor 88 (MyD88), an adaptor protein involved in TLR4 signaling, increased in cCVECs upon LPS of E. coli O55:B5 stimulation, and it was clearly colocalized with mitochondria, suggesting that LPS could affect mitochondrial function directly through TLR4 mediated signaling (Figure 1). They further analyzed the effect of LPS of E. coli O55:B5 on mitochondrial energy metabolism by detecting cellular energy consumption oxygen. Results showed that no significant change in basal oxygen consumption was observed, but the maximal respiration and spare capacity in cCVECs decreased significantly, which were not related to the decrease of cell number or cell viability. These results demonstrate that the impairment of mitochondrial energy metabolism in ECs occurs after LPS treatment. Considering that it is the respiratory chain complex proteins that play a decisive role in mitochondrial respiration, the expression of the respiratory chain complexes was examined after LPS treatment by Doll et al. They demonstrated that the expression of complex I, complex III, and complex IV decreased after LPS of E. coli O55:B5 treatment, suggesting that LPS inhibits oxidative phosphorylation of CVECs (Figure 1). Specifically inhibiting complex I or V caused a rapid rise in the permeability of cCVEC and a disruption of linear cell-cell junctions in both in vivo and in vitro experiments. Therefore, mitochondria in ECs plays a key role in maintaining BBB integrity, and LPS can damage the barrier function of the BBB by inhibiting mitochondria.

The oxidative stress and inflammation in ECs induced by LPS can damage BBB. Li et al. found that the expression of three antioxidant enzymes, glutathione peroxidase (GPX), catalase (CAT), and SOD were inhibited in Bend.3 cells after LPS treatment for 24 hours, which resulted in an increased level of ROS (Figure 1). In addition, reduced glutathione/oxidized glutathione (GSH/GSSG), an indicator of cellular antioxidant capacity, was similarly inhibited in Bend.3 cells by LPS after 24 hours’ treatment. Li et al. also showed that the activation of Nrf2 elevated the expression of antioxidant enzymes GPX, CAT, SOD as well as GSH/GSSG, which alleviated the BBB dysfunction induced by LPS. These results suggest that inhibition of the antioxidant capacity of ECs leading to a rise in the level of ROS is an important mechanism that LPS causes BBB damage. In addition, mouse BMECs were also found to produce inflammatory responses upon LPS stimulation, specifically by directly producing inflammatory factors such as interleukin (IL)-1β, IL-18, IL-6, and TNF-α, and these factors are able to mediate the damaging effects of LPS on the BBB. As oxidative stress and the inflammatory response are frequently inextricably linked, occurring concurrently in response to LPS stimulation and interacting with each other, both aspects need to be taken into consideration to protect ECs and BBB.

Based on the above studies we believe that LPS can disturb the functional status of the BBB by directly affecting processes such as proliferation or apoptosis of ECs, mitochondrial energy metabolism, inflammatory responses, as well as oxidative stress.

Basement Membrane

The composition of BBB, including vascular ECs, pericytes, and the foot processes of astrocytes, are all attached to the BM, which is composed of extracellular matrix (ECM). Once the BM is disrupted, the function of the BBB will also be impaired. MMP can directly degrade the ECM as well as digest the BM. Studies found an increased expression of MMP upon LPS treatment, which was accompanied by increased permeability of BBB.

Dal-Pizzol et al. used cecal ligation and puncture (CLP, a widely used animal model of sepsis without direct injection of LPS), which allows intestinal bacteria to invade the body cavity to establish a sepsis model and found that the increased level of LPS in the blood was accompanied by elevated BBB permeability. They further showed that the elevated permeability of BBB was most likely to be related to the increased contents and activity of MMP-2 and MMP-9 in the presence of LPS, as the injection of inhibitors of MMP-2 and MMP-9 reduced BBB permeability in model mice. Cardoso et al. also confirmed that the expression of MMP-2 and MMP-9 in rat BMECs was significantly increased after LPS of E. coli O111:B4 treatment for 4 hours, and results of sodium fluorescein and TEER assays showed obviously disrupted barrier function of BMECs (Figure 1). Inhibition of MMP-9 was also found to protect the microvascular BM in the presence of LPS in a study by Wang et al. In addition, they discovered that in response to LPS, the activity of cathepsin B, which can cleave type IV collagen, an important component of BM, was significantly increased in plasma and brain tissue, which is consistent with the finding that the distribution of type IV collagen in brain ECs became discontinuous after LPS stimulation by confocal microscopy(Figure 1). Pericytes, an essential component of the NVU, wrap around the surface of ECs and embed in BM. Nishioku et al. found that rupture of BM occurred after LPS of E. coli O55:B5 treatment and that pericytes are detached from the rupture of BM, which were accompanied by an increase of the permeability of BBB at 6 and 24 hours. Collectively, the integrity of BM is essential for maintaining the barrier function of BBB and the damage to the BM by LPS would lead to the destruction of BBB.

Microglia

As an integral part of the NVU in the BBB, microglia play an important role in maintaining the integrity of BBB. Activating microglia surround blood vessels is a protective response that prevents more pathogens from entering the brain tissue. Sumi et al. found that a small dose of LPS of E. coli O55:B5 could activate most of microglia in the rat brain microvascular endothelial cell (RBEC)/microglial co-culture system at 6 hours, which appeared as a morphological change from round to bipolar rod shape with enlarged cytoplasm and cell bodies, and an enhanced ionized calcium binding adapter molecule 1 (Iba1) staining. The activation of microglia by LPS of E. coli O55:B5 resulted in reduced RBEC permeability, and the degree of this effect was closely related to the amount as well as the degree of activation of microglia. Further immunofluorescence staining showed that due to the activation of microglia, the immunostaining activity of ZO-1, claudin-5, occludin, and other TJ proteins in the intercellular borders became fragmented, and the above dysfunction could be alleviated by NOX inhibitor. Considering that NOX is an important source of ROS, and LPS can promote the production of inflammatory factors by binding to TLR4, researchers believe that LPS in microglia destroys the structure and function of BBB by generating ROS through the TLR4-NOX signaling pathway (Figure 1). Also, Nishioku et al. demonstrated the disruption of BBB by TNF-α only in the presence of microglia (Figure 1). Bowyer et al. found that the microglia can be activated by LPS, which were particularly manifested as a mass migration to blood vessels. This study revealed that LPS activates microglia not only by directly binding to receptors on them, but also by released cytokines by damaging blood vessels.

We previously described the mechanisms that LPS enhance BBB permeability by altering P-gp activity in ECs, and some researchers believe that vascular ECs and microglia are also involved in these processes. Matsumoto et al. used the accumulation of rhodamine 123 in cells to assess the function and activity of P-gp, and discovered that LPS of E. coli O55:B5 may decrease P-gp activity in brain ECs in a microglia-dependent way after 6 hours’ treatment. They further proved that LPS can reduce the activity of P-gp by activating NOX in microglia to produce inflammatory factors such as TNF-α. PI3K-γ is a key mediator of LPS induced activation and phagocytosis of microglia. Frister et al. found that in microglia, LPS of E. coli O55:B5 increased the expression of MMP in a PI3K-γ-dependent pathway, thereby increasing the permeability of the BBB (Figure 1). Therefore, like ECs, microglia can also produce MMP to destroy the BM and open BBB. Taken together, microglia participate in damaging the barrier function of BBB in response to LPS through inflammatory cascade amplification and oxidative stress.

Astrocytes

As an integral part of the NVU of the BBB, astrocytes attach to capillaries of the CNS as end feet, and secrete various trophic factors and ECM proteins. In response to stimulation with LPS, astrocytes are activated to secrete cytokines, which are followed by activation of microglia, triggering a more drastic inflammatory response. Park et al. found that after male Sprague-Dawley rats were injected with LPS, the filaments and terminal feet of astrocytes were significantly sparse at 12 hours and 7 days, and these changes were accompanied by increased vascular permeability, which was assessed by infusing the vessel and then visualizing the concentration of extravasated vessels, suggesting that the integrity of BBB was disrupted. Studies have further shown that LPS elevates the expression of vascular endothelial growth factor A (VEGF-A) by astrocytes, followed by activating eNOS, inhibiting the expression of claudin-5 and occluding, and ultimately disrupting the barrier function of the BBB (Figure 1). Therefore, maintaining the normal morphology and function of astrocytes is an important way to preserve BBB function.

Pericytes

It is now widely recognized that pericytes are spatially the closest cells to brain ECs, and the roles of pericytes in the process of LPS damaging BBB have attracted much attention. Vutukuri et al. found that the activation of pericytes was observed in whole male C57BL/6 mice brain tissue after LPS of E. coli O55:B5 treatment for 4 hours, which was accompanied by an increase in the levels of TNF-α and IL-1β, and in the permeability of BBB. Smyth et al. found translocation of NF-κB into the nucleus in pericytes after LPS of E. coli O26:B6 treatment for 1 hour, indicating an activated inflammatory response in pericytes in the presence of LPS (Figure 1). Further studies have found that the inflammatory response mediated by signal transducer and activator of transcription 1(STAT1), and similar to others against dodecapentaplegic-2/3(SMAD2/3) is also very similar in pericytes and ECs. These results suggest that inflammatory responses mediated by pericytes and ECs have a concerted response. Kovac et al. found that LPS of S. typhimurium can stimulate pericytes to produce many chemokines and pro-inflammatory factors. Notably, IL-9 generated by pericytes in response to LPS of S. typhimurium can further stimulate astrocytes to produce chemokine-ligand-20 (CCL-20), which promotes T lymphocyte infiltration into the CNS and amplifies the inflammatory response in vivo. Pericytes may therefore play a role in the inflammatory response in the brain tissue upon LPS stimulation to disrupt the barrier function of BBB.

Neutrophils

The BBB prevents peripheral immune cells from entering the brain tissue, but when the BBB barrier function is broken, they can penetrate the brain tissue, highlighting that the systemic inflammatory response may compromise the BBB’s barrier function. Park et al. found that neutrophils were infiltrated in brain tissue in male Sprague–Dawley rats after treated with LPS for 12 hours and 7 days, and BBB destruction occurred simultaneously. Haileselassie et al. showed that vascular leukocyte adhesion factors such as vascular cell adhesion molecule-1(VCAM-1) and intercellular adhesion molecule-1(ICAM-1) increased in LPS model of sepsis after 24 hours’ treatment, indicating that inflammatory cells have adhered and transmigrated to vessels (Figure 1). The CXCR2, a G protein coupled receptor, is involved in a series of leukocyte cellular responses, such as cell recruitment and migration (Figure 1). Wu et al. found that neutrophils were significantly infiltrated in the cerebral cortex of mice after LPS of E. coli O111:B4 injection for 24 hours, while blocking CXCR2 significantly alleviated the effects (Figure 1). Silwedel et al. also observed that LPS of E. coli O55:B5 caused an increased expression of C-X-C motif chemokine ligand (CXCL)11 and a decreased level of CXCL12 after 4 hours’ treatment, which resulted from the increase of leukocyte migration. In summary, LPS can induce the migration of neutrophils to the brain tissue. However, studies found that LPS of E. coli O111:B4 elevates CXCR2 on brain ECs but reduces CXCR2 on neutrophils, suggesting that ECs are important in inducing neutrophil infiltration under the stimulation of LPS. As an important part of systemic inflammation, the response of neutrophils is specifically manifested as mediating and amplifying inflammation in the brain tissue, thereby destroying the structure of the BBB.

BBB and SAE

Sepsis, a pathological process causing dysfunction of one’s own organs due to bacterial infection and its resulting dysregulated inflammatory response, is the leading cause of death in critically ill patients with significant morbidity and mortality, representing a high proportion of readmissions after treatment discharge. Sepsis often leads to multiple organ dysfunctions, such as the heart, liver as well as kidneys, and causes severe complications. The brain dysfunction caused by sepsis, namely SAE, is one of the most common and serious complications. The CNS of patients with SAE often does not have obvious infections, instead neuroinflammation and oxidative stress appear in brain tissue, and patients have significant symptoms such as cognitive dysfunction, memory decline, and clinical coma or confusion. Given that disruption of the BBB is an important mechanism underlying the development of SAE and would confer a poor prognosis and long-term impact on quality of life, we will focus on the relationship between BBB destruction and SAE.

BBB Disruption and SAE

It is commonly assumed that neuroinflammation produced by oxidative stress and mitochondrial dysfunction are the primary pathophysiological processes implicated in the development of SAE.. In normal circumstances, only a small number of inflammatory factors such as TNF-α, IL-1, and IL-6, from the systemic circulation may pass through the BBB to enter the brain. However, the disruption of BBB will make a wide range of inflammatory cytokines, neurotoxins, complement as well as pathogens to enter the brain tissue when systemic inflammation occurs. Not only that, the NVU that makes up the BBB also mediates partial inflammatory responses, oxidative stress, and other reactions, for example, activating microglia to release NO, cytokines, and ROS, to aggravate BBB dysfunction in turn, so BBB disruption can be not only a cause but also a consequence of SAE.

Alexander et al. found that after intraperitoneal injection of LPS of E. coli O55:B55, the concentration of TNF-α, a key metabolic mediator in sepsis in the blood, increased significantly after 1 hour’s treatment, which resulted in a decrease in the integrity of BBB, infiltration of neutrophils into the brain and the subsequent SAE symptoms. An increased activation of glial cells, as well as neuronal apoptosis, was observed over time by using LPS of E. coli O127:B8 to induce peripheral inflammatory responses by Semmler et al. In a sepsis model with CLP, Imamura et al. found that the LPS level in the blood increased, the BBB was destroyed, the expression of IL-1β and its receptors in the brain tissue increased, and brain inflammation occurred. They also showed that IL-1β was one of the first increased inflammatory factors in sepsis and the dysfunctional BBB, in turn, allowed other inflammatory mediators including IL-1β to enter the brain as well as the cerebrospinal fluid, consequently leading to the appearance of cognitive impairment. Mina et al. used IL-1β receptor antagonist to antagonize IL-1β, which reversed BBB damage and cognitive impairment after brain oxidative damage, confirming that IL-1β is an important factor mediating cognitive impairment in sepsis.

It is known that during the early stage of sepsis, there is an activation of glial cells at the brain vessels as well as the secretion of large amounts of cytokines, which leads to the disrupted BBB and symptoms of brain inflammation. Microglia are brain resident macrophages that are normally in a resting state and can immediately go into an activated state upon stimulation by injury or factors like LPS, after which they rapidly undergo proliferation, migration, engulf and secrete cytokines. Normal microglial responses in brain tissue are obligatory for phagocytic clearance of damaged neural cells and tissue debris, but persistent or vigorous microglial responses can damage the CNS. When BBB permeability rises, especially in the hippocampus, a large number of cytokines, such as TNF-α and IL-6, enter the brain tissue to cause oxidative stress and inflammatory responses in microglia, which plays a major role in the development of cognitive impairment in SAE. Moreover, the oxidative stress response mediated by NOX in microglia manifesting as excessive ROS production, is also involved in the process of LPS damage to TJ and AJ proteins and SAE occurrence. Collectively, microglia can be activated by LPS or cytokines such as TNF-α and IL-6, and destroy the BBB during the initial phase of sepsis by directly mediating neuroinflammation in the brain and participating in the direct spread of neuroinflammation in the course of SAE.

Sepsis is a dysregulated systemic inflammatory response that is initially aimed at eradicating pathogens or pathogenic factors, but the abnormal inflammatory response would cause BBB disruption and neuronal damage, accompanied by the appearance of cognitive dysfunction, mental disorder, and other clinical symptoms. Clinical studies demonstrated BBB damage in patients who died of sepsis, and a significant decrease of TJ proteins. Sharshar et al. demonstrated that brain damage caused by sepsis was specifically manifested as an elevated permeability of BBB by magnetic resonance imaging, which is strongly associated with poor prognosis. Disrupted BBB with a rise in permeability was also observed in a pathological model of sepsis through CLP. These results indicated that impaired BBB may serve as an initiating link as well as a driver of SAE, which leads to an infiltration of various cytokines and leukocytes in brain tissue and causes neuronal apoptosis and dysfunction, ending up with a series of neuropsychiatric symptoms with a high mortality.

The BBB Is a Validated Target for the Treatment of SAE

Sepsis is an abnormal or dysregulated host response to stimuli from external factors as well as internal organ dysfunction. Current studies have redefined sepsis as ‘life-threatening organ dysfunction caused by a dysregulated host response to infection’.To date, sepsis has been a major public health problem worldwide and a leading cause of the death of critical illness. Survivors of sepsis usually have physical and cognitive dysfunctions, giving rise to a large burden on society and patients’ families. SAE, as one of the most serious and frequent complications of sepsis, leads to an extremely poor prognosis for patients as well as a substantial reduction patient’s life quality. Here, we will discuss the possibility of BBB as an effective target for treating SAE. As LPS can disrupt the structure and function of the BBB, and the damaged BBB is closely related to the development of SAE, we believe that targeting the BBB may be an effective strategy to prevent and treat SAE.

Glial cells play an important role in both LPS disruption of the BBB and the development of SAE after BBB disruption. Monique et al. showed that inhibition of the activity of microglia could decrease the permeability of BBB that were elevated by the actions of systemic cytokines, and reverse the long-term cognitive impairment. They further found that the protective effect by inhibiting microglia on BBB is partly through the cluster of differentiation (CD)40-CD40 ligand pathway, and anti-CD40 treatment ameliorated long-term cognitive impairment caused by sepsis (Figure 2). Studies in recent years have found that dexmedetomidine, a clinical drug commonly used for sedation, plays a neuroprotective role through an anti-inflammatory mechanism. Mei et al. found that dexmedetomidine could activate 2A adrenoceptors on astrocytes but not microglia to decrease proinflammatory factors in the brain, preserve BBB integrity, and enhance learning and memory performance by activating 2A adrenoceptors on astrocytes in septic mice (Figure 2). It was shown that the high mobility group box protein 1 (HMGB1) released from astrocytes and microglia is an important factor in regulating BBB permeability in inflammatory response (Figure 2). Dexmedetomidine can improve the integrity of BBB as well as cognitive impairment by inhibiting HMGB1. Therefore, HMGB1 may represent a new target for the treatment of sepsis and SAE. Several studies have demonstrated the pro-inflammatory effects of hyperglycemia. Huang et al. found that the activity of astrocytes and microglia, as well as that of NF-κB and MAPKs was inhibited after using insulin to control blood glucose in Sprague-Dawley rats, which accompanied by reduced permeability of BBB and alleviated SAE, showing full recovery of the mechanical withdrawal threshold and thermal withdrawal latency as well as an increased electroencephalography frequency (Figure 2). Besides, studies have also confirmed that insulin can directly inhibit brain tissue inflammatory response and oxidative stress injury, which consequently improves brain tissue damage. Omarigliptin is a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor developed for the treatment of type 2 diabetes. Studies have found that Omarigliptin can not only maintain the integrity of the BBB by inhibiting neuroinflammation, but also reduce the expression of MMP-2 and MMP-9 to protect TJs protein. These results suggest that, for the management of sepsis patients in intensive care unit (ICU), attentions should also be paid to the blood glucose changes and the application of insulin, to reduce the likelihood of SAE. Overall, protecting the BBB by inhibiting the activity of glial cells may be helpful for the treatment of SAE. But studies also have found that in the early stage of SAE, the morphology of glial cells begins to change without obvious disruption of the BBB. Therefore, introducing prophylactic drugs that inhibit neuroinflammation would be helpful to avoid the rapid deterioration of SAE after BBB disruption.

NF-κB, as a proinflammatory cell transcription factor that exists in almost all cells, was found to participate in the BBB disruption by LPS. Nod-like receptor protein 3 (NLRP3) plays an important role in the inflammation cascade by amplifying the inflammation response. Chen et al. found a suppression of the NF-kB/NLRP3 inflammatory pathway by directly binding to the promoter region of NLRP3, which resulted in a decreased cell apoptosis and inflammation, and an alleviation of BBB disruption and SAE. Kikuchi et al. showed that inhibition of poldip2 could attenuate BBB disruption caused by sepsis by regulating the nuclear translocation process of NF-κB as well as Cox-2 expression, preventing the occurrence and development of SAE (Figure 2). Di Bella et al. found that citrate-covered gold nanoparticles (Cit-AuNP) could prevent the process of NF-κB translocation to the nucleus by decreasing the phosphorylation of inhibitor of kappa B alpha (IκBα), which was followed by decreased expression of pro-inflammatory factor ICAM-1 on leukocytes and reduced adhesion of leukocyte to the endothelium of intracerebral blood vessels, ultimately alleviating the inflammatory response in the brain by BBB protection and reducing the occurrence of SAE during sepsis (Figure 2). Wang et al. found that by inhibiting soluble epoxide hydrolase (sEH) using TPPU(N-[1-(1-oxopropyl)-4-piperidinyl]-N’-[4-(trifluoromethoxy)phenyl)-urea), which is required for the activity of epoxyeicosatrienoic acids (EETs), a substance involved in maintaining the intact structure of cerebral blood vessels, the barrier function of BBB was improved, followed by an alleviation of long-term encephalopathy in CLP model mice (Figure 2). Myeloperoxidase (MPO) in microglia and neutrophils not only regulates inflammation-related signaling pathways but also promotes ROS production to mediate oxidative stress. Sphingolipid, as the biologically active family of lipids found, plays a key role in maintaining the structure and function of the BBB, and is also closely related to the pathological state of the CNS. Ullen et al. found that 4-aminobenzoic acid hydrazide (ABAH), an inhibitor of MPO, alleviated BBB dysfunction induced by LPS by maintaining the homeostasis of sphingolipid, thereby improving the function of brain (Figure 2). Fish oil (FO) is an important source of long-chain n-3 polyunsaturated fatty acids (PUFAs) with immunomodulatory and anti-inflammatory effects. Recent studies have found that FO enriched lipid emulsion is able to prevent long-term cognitive impairment caused by sepsis, by protecting the BBB as well as inhibiting the activity of MPO (Figure 2). Interestingly, Margotti et al. found that neutrophils infiltration into brain tissue due to BBB rupture caused an increased production of MPO, accompanied by lipid oxidative damage in the hippocampus and prefrontal cortex, suggesting a vicious circle between BBB destruction and MPO production. These results suggested that MPO may become a potential drug target for the treatment of brain dysfunction caused by sepsis. Besides, anti-inflammatory and antioxidant drugs, such as metformin, platonin have been shown to exhibit neuroprotective effects, and can improve the decreased expression of TJ proteins induced by sepsis, thereby improving BBB function and attenuating sepsis-induced brain injury. Therefore, anti-inflammation and anti-oxidation represent important strategies to protect BBB and brain tissues.

Mitochondria are vital to cell metabolism because they provide ATP for living activities via oxidative phosphorylation, and play an important part in the cell apoptosis and programmed cell death processes. Impairment of mitochondrial energy metabolism or abnormal apoptosis in BMECs both affect the barrier function of BBB. Therefore, mitochondria may represent a potential strategy in the treatment of SAE. Haileselassie et al. found that the mitochondrial dysfunction mediated by the interaction of Drp1-Fis1 in response to LPS leads to increased permeability of the BBB and a direct toxic effect on primary cortical ECs, but the above results can all be eliminated by Drp1-Fis1 interaction inhibitor P110 (Figure 2). So, inhibiting mitochondrial dysfunction to protect both BBB and neurons could be a potentially new therapeutic strategy for treating SAE. Omi/high-temperature requirement serine protease A2 (HtrA2), a proapoptotic serine protease mainly found in and released from mitochondria, is found to be involved in the development of BBB dysfunction and SAE induced by sepsis through a caspase-dependent mitochondrial pathway. After inhibiting Omi/HtrA2 translocation from mitochondria to the cytosol by UCF-101(an inhibitor of Omi/HtrA2), oxidative damage in the brain tissue and cognitive dysfunction induced by sepsis were significantly improved (Figure 2). Further studies found that inhibiting Omi/HtrA2 not only protects neurons, but also alleviates the apoptosis of brain ECs and the decreased TJs protein induced by LPS (Figure 2). In addition, Xu et al. alleviated BBB disruption induced by sepsis and protected synaptic plasticity by inhibiting caspase-1-mediated apoptosis, thus improving the cognitive impairment in a mouse model of sepsis. Therefore, improving mitochondrial dysfunction and related apoptosis pathways are helpful to protect neurons and maintain the barrier function of BBB, which represent a new potential treatment strategy for SAE.

Pathogenic factors in sepsis such as LPS, after binding to TLR4, result in dysregulated inflammatory responses through complex immune activation, so targeting immune activating responses that inhibit neuroinflammation may be protective against BBB disruption by sepsis. Intravenous immunoglobulin is a therapeutic treatment with anti-infective, anti-inflammatory, and immunomodulatory effects. Studies showed that intravenous immunoglobulin can serve as an important part of the adjuvant treatment of sepsis, but for 40 years the method is still controversial. Esen et al. found that the injection of immunoglobulin G or a combination of immunoglobulin A and M both exerted neuroprotective effects, which improved the integrity of the BBB, and alleviated the symptoms of sepsis in rats (Figure 2). Considering the regulatory effects of immunoglobulins on the complement system and the finding that inhibition of complement C5a could protect the BBB during sepsis, the protective effect of immunoglobulins on the BBB is most likely achieved through the regulation of the complement system (Figure 2). Overall, as the dysregulated inflammatory response in sepsis is coupled with the initial immunomodulatory response, more studies could be performed to refine novel strategies to treat SAE by suppressing the immune activation response of excessive neuroinflammation.

Conclusion and Future Directions

The BBB is essential for maintaining homeostasis within the brain’s biochemical environment. As the barrier of CNS, the low permeability of BBB separates neural tissue from circulating blood, and the infiltration of leukocytes (such as neutrophils, lymphocytes) in CNS is much less than that in peripheral tissues, CNS was often considered as an immune privileged site in the past. However, BBB is often disturbed in response to various pathogenic agents, causing the entry of cytokines, pathogens as well as immune cells from blood into the CNS through BBB, which is closely associated with the occurrence and development of CNS diseases such as SAE.

This review discussed the mechanisms of the BBB damage by LPS, a major pathogenic agent of sepsis, through direct and indirect actions. The direct damage on the BBB by LPS is by disrupting the BBB’s structure. Among the mechanisms, the paracellular pathways maintained by TJs and AJs, the transcellular pathway, P-gp, and vesicle trafficking are the fundamental forms by which LPS raises the permeability of the BBB and disrupts its barrier function. The paracellular and transcellular pathways can be regarded as central links in future studies on how to protect the BBB from being damaged by toxic substances like LPS. As the basic components of BBB, the endothelium and BM, are the targets of LPS. Once their energy metabolism status is abnormally altered, a direct disruption of the BBB’s structure would occur and thus its barrier function cannot be maintained. Besides, LPS also damages the BBB indirectly by acting on microglia, astrocytes, pericytes, and neutrophils. Notably, the roles performed by these cells in the disruption of the BBB by LPS may be interpreted as a succession or amplification, implying that the effects on the structure and function of the BBB by LPS are largely or even entirely through the mechanisms detailed in the direct actions section. Recent studies have found that the communication between cells that make up the NVU and the basic structure of the BBB was more complex and diverse than previously realized, and cells of the NVU were involved in dynamically regulating the barrier function of the BBB. Therefore, more researches are needed to explore how to raise the infiltration of drugs into the brain to act on these cells, and thus to protect the BBB.

Sepsis attracts the attention of clinicians and researchers due to the poor prognosis of patients in critical care medicine. In this review, we discussed the link between the BBB disruption and the occurrence of SAE, aiming at finding novel strategies to treat SAE by maintaining the barrier function of BBB. Systemic injection of LPS has been shown to cause damage to the BBB of recipient animals, resulting in the subsequent entry of peripheral cytokines into the brain. It is believed that the main contribution of the damaged BBB to the occurrence and development of SAE is to cause a large number of inflammatory factors and neurotoxins to enter the brain tissue, accompanied by immune cells in the brain tissue such as microglia being activated during systemic inflammation, thereby mediating neuroinflammation and oxidative stress. Subsequently, inflammation and oxidative stress in the brain tissue, in turn, amplify the extent of BBB disruption, which creates a vicious cycle that would fuel the generation and progression of SAE. Therefore, restoring the barrier function of BBB may serve as an effective approach to treat SAE.

According to current research, neuroinflammation and oxidative stress are key factors in the development of SAE, and inhibiting inflammatory reactions has a significant impact on SAE therapy.. Therefore, elucidating mechanisms of the inflammation and oxidative stress that are closely related to the occurrence of SAE will be important for the development of drugs to treat SAE. More importantly, it was found that drugs that are generally recognized to have the ability to inhibit inflammatory and oxidative stress responses also have neuroprotective effect. It is important to note that the efficacy of intravenous immunoglobulin therapy for sepsis has been controversial, but targeting the pathway that inhibits the immune activation response to neuroinflammation is hoped to lead the way from the very beginning to the development of SAE and is likely turn out to be a brand-new strategy in the treatment of SAE. We believe that researchers may try to block the damage on the BBB by LPS to prevent and treat SAE in the further studies.

Author Contributions

XP and YL conceived and wrote the manuscript. SH and ZL conceived the figure. YL and LZ reviewed the original draft. All authors contributed to the article and approved the submitted version.

Funding

This study was funded by Innovation and Entrepreneurship Training Program of Sichuan province (S202010632272).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References 231

  1. 1.

    Akira S. Takeda K. (2004 ). Toll-Like Receptor Signalling. Nat. Rev. Immunol. 4, 499–511

    Not in our library10.1038/nri1391

  2. 2.

    Alelwani W. Elmorsy E. Kattan S. W. Babteen N. A. Alnajeebi A. M. Al-Ghafari A.. (2020 ). Carbamazepine Induces a Bioenergetics Disruption to Microvascular Endothelial Cells From the Blood-Brain Barrier. Toxicol. Lett. 333, 184–191

    Not in our library10.1016/j.toxlet.2020.08.006

  3. 3.

    Alexander J. J. Jacob A. Cunningham P. Hensley L. Quigg R. J. (2008 ). TNF Is a Key Mediator of Septic Encephalopathy Acting Through Its Receptor, TNF Receptor-1. Neurochem. Int. 52, 447–456

    Not in our library10.1016/j.neuint.2007.08.006

  4. 4.

    Alexandrov P. N. Hill J. M. Zhao Y. Bond T. Taylor C. M. Percy M. E.. (2020 ). Aluminum-Induced Generation of Lipopolysaccharide (LPS) From the Human Gastrointestinal (GI)-Tract Microbiome-Resident Bacteroides Fragilis. J. Inorg Biochem. 203, 110886

    Not in our library10.1016/j.jinorgbio.2019.110886

  5. 5.

    Alkabie S. Basivireddy J. Zhou L. Roskams J. Rieckmann P. Quandt J. A. (2016 ). SPARC Expression by Cerebral Microvascular Endothelial Cells In Vitro and Its Influence on Blood-Brain Barrier Properties. J. Neuroinflammation. 13, 225

    Not in our library10.1186/s12974-016-0657-9

  6. 6.

    Amorim R. G. Guedes G. D. S. Vasconcelos S. M. L. Santos J. C. F. (2019 ). Kidney Disease in Diabetes Mellitus: Cross-Linking Between Hyperglycemia, Redox Imbalance and Inflammation. Arq Bras. Cardiol. 112, 577–587

    Not in our library10.5935/abc.20190077

  7. 7.

    Andreone B. J. Chow B. W. Tata A. Lacoste B. Ben-Zvi A. Bullock K.. (2017 ). Blood-Brain Barrier Permeability Is Regulated by Lipid Transport-Dependent Suppression of Caveolae-Mediated Transcytosis. Neuron 94, 581–594.e585

    Not in our library10.1016/j.neuron.2017.03.043

  8. 8.

    Annane D. Sharshar T. (2015 ). Cognitive Decline After Sepsis. Lancet Respir. Med. 3, 61–69

    Not in our library10.1016/s2213-2600(14)70246-2

  9. 9.

    Anthoney N. Foldi I. Hidalgo A. (2018 ). Toll and Toll-Like Receptor Signalling in Development. Development 145, dev156018

    Not in our library10.1242/dev.156018

  10. 10.

    Argaw A. T. Asp L. Zhang J. Navrazhina K. Pham T. Mariani J. N.. (2012 ). Astrocyte-Derived VEGF-A Drives Blood-Brain Barrier Disruption in CNS Inflammatory Disease. J. Clin. Invest. 122, 2454–2468

    Not in our library10.1172/jci60842

  11. 11.

    Argaw A. T. Gurfein B. T. Zhang Y. Zameer A. John G. R. (2009 ). VEGF-Mediated Disruption of Endothelial CLN-5 Promotes Blood-Brain Barrier Breakdown. Proc. Natl. Acad. Sci. U. S. A. 106, 1977–1982

    Not in our library10.1073/pnas.0808698106

  12. 12.

    Armulik A. Genove G. Mae M. Nisancioglu M. H. Wallgard E. Niaudet C.. (2010 ). Pericytes Regulate the Blood-Brain Barrier. Nature 468, 557–561

    Not in our library10.1038/nature09522

  13. 13.
  14. 14.

    Basta M. (2008 ). Ambivalent Effect of Immunoglobulins on the Complement System: Activation Versus Inhibition. Mol. Immunol. 45, 4073–4079

    Not in our library10.1016/j.molimm.2008.07.012

  15. 15.

    Bauer B. Hartz A. Fricker G. Miller D. (2004 ). Pregnane X Receptor Up-Regulation of P-Glycoprotein Expression and Transport Function at the Blood-Brain Barrier. Mol. Pharmacol. 66, 413–419

    Not in our library10.1124/mol.66.3

  16. 16.

    Bauer M. Karch R. Wulkersdorfer B. Philippe C. Nics L. Klebermass E. M.. (2019 ). A Proof-Of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier. J. Nucl. Med. 60, 486–491

    Not in our library10.2967/jnumed.118.216432

  17. 17.

    Berger R. E. Rivers E. Levy M. M. (2017 ). Management of Septic Shock. N. Engl. J. Med. 376, 2282–2285

    Not in our library10.1056/nejmclde1705277

  18. 18.

    Biftu T. Sinha-Roy R. Chen P. Qian X. Feng D. Kuethe J. T.. (2014 ). Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes. J. Med. Chem. 57, 3205–3212

    Not in our library10.1021/jm401992e

  19. 19.

    Blecharz-Lang K. G. Wagner J. Fries A. Nieminen-Kelha M. Rosner J. Schneider U. C.. (2018 ). Interleukin 6-Mediated Endothelial Barrier Disturbances Can Be Attenuated by Blockade of the IL6 Receptor Expressed in Brain Microvascular Endothelial Cells. Transl. Stroke Res. 9, 631–642

    Not in our library10.1007/s12975-018-0614-2

  20. 20.

    Bock F. J. Tait S. W. G. (2020 ). Mitochondria as Multifaceted Regulators of Cell Death. Nat. Rev. Mol. Cell Biol. 21, 85–100

    Not in our library10.1038/s41580-019-0173-8

  21. 21.

    Boitsova E. B. Morgun A. V. Osipova E. D. Pozhilenkova E. A. Martinova G. P. Frolova O. V.. (2018 ). The Inhibitory Effect of LPS on the Expression of GPR81 Lactate Receptor in Blood-Brain Barrier Model In Vitro. J. Neuroinflammation. 15, 196

    Not in our library10.1186/s12974-018-1233-2

  22. 22.
  23. 23.

    Bowyer J. F. Sarkar S. Burks S. M. Hess J. N. Tolani S. O’Callaghan J. P.. (2020 ). Microglial Activation and Responses to Vasculature That Result From an Acute LPS Exposure. Neurotoxicology 77, 181–192

    Not in our library10.1016/j.neuro.2020.01.014

  24. 24.

    Bradshaw A. D. Sage E. H. (2001 ). SPARC, A Matricellular Protein That Functions in Cellular Differentiation and Tissue Response to Injury. J. Clin. Invest. 107, 1049–1054

    Not in our library10.1172/jci12939

  25. 25.

    Buendia I. Michalska P. Navarro E. Gameiro I. Egea J. Leon R. (2016 ). Nrf2-ARE Pathway: An Emerging Target Against Oxidative Stress and Neuroinflammation in Neurodegenerative Diseases. Pharmacol. Ther. 157, 84–104

    Not in our library10.1016/j.pharmthera.2015.11.003

  26. 26.

    Cardoso F. L. Brites D. Brito M. A. (2010 ). Looking at the Blood-Brain Barrier: Molecular Anatomy and Possible Investigation Approaches. Brain Res. Rev. 64, 328–363

    Not in our library10.1016/j.brainresrev.2010.05.003

  27. 27.

    Cardoso F. L. Kittel A. Veszelka S. Palmela I. Toth A. Brites D.. (2012 ). Exposure to Lipopolysaccharide and/or Unconjugated Bilirubin Impair the Integrity and Function of Brain Microvascular Endothelial Cells. PloS One 7, e35919

    Not in our library10.1371/journal.pone.0035919

  28. 28.

    Carey A. N. Fisher D. R. Bielinski D. F. Cahoon D. S. Shukitt-Hale B. (2020 ). Walnut-Associated Fatty Acids Inhibit LPS-Induced Activation of BV-2 Microglia. Inflammation 43, 241–250

    Not in our library10.1007/s10753-019-01113-y

  29. 29.

    Casilli F. Bianchini A. Gloaguen I. Biordi L. Alesse E. Festuccia C.. (2005 ). Inhibition of Interleukin-8 (CXCL8/IL-8) Responses by Repertaxin, a New Inhibitor of the Chemokine Receptors CXCR1 and CXCR2. Biochem. Pharmacol. 69, 385–394

    Not in our library10.1016/j.bcp.2004.10.007

  30. 30.

    Catalao C. H. R. Santos-Junior N. N. da Costa L. H. A. Souza A. O. Alberici L. C. Rocha M. J. A. (2017 ). Brain Oxidative Stress During Experimental Sepsis Is Attenuated by Simvastatin Administration. Mol. Neurobiol. 54, 7008–7018

    Not in our library10.1007/s12035-016-0218-3

  31. 31.

    Ceretta L. B. Reus G. Z. Abelaira H. M. Ribeiro K. F. Zappellini G. Felisbino F. F.. (2012 ). Increased Oxidative Stress and Imbalance in Antioxidant Enzymes in the Brains of Alloxan-Induced Diabetic Rats. Exp. Diabetes Res. 2012, 302682

    Not in our library10.1155/2012/302682

  32. 32.

    Chen Y. J. Chen F. L. Chen J. H. Wu M. M. Chen Y. L. Chien D. S.. (2019 ). Epidemiology of Sepsis in Taiwan. Med. (Baltimore) 98, e15725

    Not in our library10.1097/md.0000000000015725

  33. 33.

    Cheng X. Yang Y. L. Yang H. Wang Y. H. Du G. H. (2018 ). Kaempferol Alleviates LPS-Induced Neuroinflammation and BBB Dysfunction in Mice via Inhibiting HMGB1 Release and Down-Regulating TLR4/MyD88 Pathway. Int. Immunopharmacol. 56, 29–35

    Not in our library10.1016/j.intimp.2018.01.002

  34. 34.

    Chen D. Li X. Zhang L. Zhu M. Gao L. (2018 ). A High-Fat Diet Impairs Mitochondrial Biogenesis, Mitochondrial Dynamics, and the Respiratory Chain Complex in Rat Myocardial Tissues. J. Cell Biochem. 119, 9602

    Not in our library10.1002/jcb.27068

  35. 35.
  36. 36.

    Chen K. Wang N. Diao Y. Dong W. Sun Y. Liu L.. (2017 ). Hydrogen-Rich Saline Attenuates Brain Injury Induced by Cardiopulmonary Bypass and Inhibits Microvascular Endothelial Cell Apoptosis Via the PI3K/Akt/GSK3beta Signaling Pathway in Rats. Cell Physiol. Biochem. 43, 1634–1647

    Not in our library10.1159/000484024

  37. 37.

    Chen Q. Yu W. Shi J. Shen J. Gao T. Zhang J.. (2014 ). Insulin Alleviates the Inflammatory Response and Oxidative Stress Injury in Cerebral Tissues in Septic Rats. J. Inflammation (Lond). 11, 18

    Not in our library10.1186/1476-9255-11-18

  38. 38.

    Chien H. C. Colas C. Finke K. Springer S. Stoner L. Zur A. A.. (2018 ). Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (Lat1). J. Med. Chem. 61, 7358–7373

    Not in our library10.1021/acs.jmedchem.8b01007

  39. 39.

    Chlenski A. Cohn S. L. (2010 ). Modulation of Matrix Remodeling by SPARC in Neoplastic Progression. Semin. Cell Dev. Biol. 21, 55–65

    Not in our library10.1016/j.semcdb.2009.11.018

  40. 40.

    Cho S. C. Park M. C. Keam B. Choi J. M. Cho Y. Hyun S.. (2010 ). DDS, 4,4’-Diaminodiphenylsulfone, Extends Organismic Lifespan. Proc. Natl. Acad. Sci. U. S. A. 107, 19326–19331

    Not in our library10.1073/pnas.1005078107

  41. 41.

    Chow J. C. Young D. W. Golenbock D. T. Christ W. J. Gusovsky F. (1999 ). Toll-Like Receptor-4 Mediates Lipopolysaccharide-Induced Signal Transduction. J. Biol. Chem. 274, 10689–10692

    Not in our library10.1074/jbc.274.16.10689

  42. 42.

    Chrissobolis S. Faraci F. M. (2008 ). The Role of Oxidative Stress and NADPH Oxidase in Cerebrovascular Disease. Trends Mol. Med. 14, 495–502

    Not in our library10.1016/j.molmed.2008.09.003

  43. 43.

    Coisne C. Engelhardt B. (2011 ). Tight Junctions in Brain Barriers During Central Nervous System Inflammation. Antioxid. Redox. Signal. 15, 1285–1303

    Not in our library10.1089/ars.2011.3929

  44. 44.

    Comim C. M. Vilela M. C. Constantino L. S. Petronilho F. Vuolo F. Lacerda-Queiroz N.. (2011 ). Traffic of Leukocytes and Cytokine Up-Regulation in the Central Nervous System in Sepsis. Intensive Care Med. 37, 711–718

    Not in our library10.1007/s00134-011-2151-2

  45. 45.

    Cornelius C. Crupi R. Calabrese V. Graziano A. Milone P. Pennisi G.. (2013 ). Traumatic Brain Injury: Oxidative Stress and Neuroprotection. Antioxid. Redox. Signal. 19, 836–853

    Not in our library10.1089/ars.2012.4981

  46. 46.
  47. 47.

    Dal-Pizzol F. Rojas H. A. dos Santos E. M. Vuolo F. Constantino L. Feier G.. (2013 ). Matrix Metalloproteinase-2 and Metalloproteinase-9 Activities Are Associated With Blood-Brain Barrier Dysfunction in an Animal Model of Severe Sepsis. Mol. Neurobiol. 48, 62–70

    Not in our library10.1007/s12035-013-8433-7

  48. 48.

    Daneman R. Prat A. (2015 ). The Blood-Brain Barrier. Cold Spring Harb. Perspect. Biol. 7, a020412

    Not in our library10.1101/cshperspect.a020412

  49. 49.

    Danielski L. G. Giustina A. D. Badawy M. Barichello T. Quevedo J. Dal-Pizzol F.. (2018 ). Brain Barrier Breakdown as a Cause and Consequence of Neuroinflammation in Sepsis. Mol. Neurobiol. 55, 1045–1053

    Not in our library10.1007/s12035-016-0356-7

  50. 50.

    Deli M. A. Abraham C. S. Kataoka Y. Niwa M. (2005 ). Permeability Studies on In Vitro Blood-Brain Barrier Models: Physiology, Pathology, and Pharmacology. Cell Mol. Neurobiol. 25, 59–127

    Not in our library10.1007/s10571-004-1377-8

  51. 51.

    Della Giustina A. Goldim M. P. Danielski L. G. Florentino D. Garbossa L. Joaquim L.. (2020 ). Fish Oil-Rich Lipid Emulsion Modulates Neuroinflammation and Prevents Long-Term Cognitive Dysfunction After Sepsis. Nutrition 70, 110417

    Not in our library10.1016/j.nut.2018.12.003

  52. 52.
  53. 53.

    Dhaya I. Griton M. Raffard G. Amri M. Hiba B. Konsman J. P. (2018 ). Bacterial Lipopolysaccharide-Induced Systemic Inflammation Alters Perfusion of White Matter-Rich Regions Without Altering Flow in Brain-Irrigating Arteries: Relationship to Blood-Brain Barrier Breakdown? J. Neuroimmunol. 314, 67–80

    Not in our library10.1016/j.jneuroim.2017.11.009

  54. 54.

    Di Bella D. Ferreira J. P. S. Silva R. N. O. Echem C. Milan A. Akamine E. H.. (2021 ). Gold Nanoparticles Reduce Inflammation in Cerebral Microvessels of Mice With Sepsis. J. Nanobiotechnology. 19, 52

    Not in our library10.1186/s12951-021-00796-6

  55. 55.

    Di Rosa R. Pietrosanti M. Luzi G. Salemi S. D’Amelio R. (2014 ). Polyclonal Intravenous Immunoglobulin: An Important Additional Strategy in Sepsis? Eur. J. Intern. Med. 25, 511–516

    Not in our library10.1016/j.ejim.2014.05.002

  56. 56.

    Dohgu S. Banks W. A. (2008 ). Lipopolysaccharide-Enhanced Transcellular Transport of HIV-1 Across the Blood-Brain Barrier Is Mediated by the P38 Mitogen-Activated Protein Kinase Pathway. Exp. Neurol. 210, 740–749

    Not in our library10.1016/j.expneurol.2007.12.028

  57. 57.

    Doll D. N. Hu H. Sun J. Lewis S. E. Simpkins J. W. Ren X. (2015 ). Mitochondrial Crisis in Cerebrovascular Endothelial Cells Opens the Blood-Brain Barrier. Stroke 46, 1681–1689

    Not in our library10.1161/strokeaha.115.009099

  58. 58.

    Du H. Wang S. (2020 ). Omarigliptin Mitigates Lipopolysaccharide-Induced Neuroinflammation and Dysfunction of the Integrity of the Blood-Brain Barrier. ACS Chem. Neurosci. 11, 4262–4269

    Not in our library10.1021/acschemneuro.0c00537

  59. 59.

    Endl E. Hollmann C. Gerdes J. (2001 ). Antibodies Against the Ki-67 Protein: Assessment of the Growth Fraction and Tools for Cell Cycle Analysis. Methods Cell Biol. 63, 399–418

    Not in our library10.1016/s0091-679x(01)63022-x

  60. 60.

    Erikson K. Tuominen H. Vakkala M. Liisanantti J. H. Karttunen T. Syrjala H.. (2020 ). Brain Tight Junction Protein Expression in Sepsis in an Autopsy Series. Crit. Care 24, 385

    Not in our library10.1186/s13054-020-03101-3

  61. 61.

    Esen F. Orhun G. Ozcan P. E. Senturk E. Kucukerden M. Giris M.. (2017 ). Neuroprotective Effects of Intravenous Immunoglobulin Are Mediated Through Inhibition of Complement Activation and Apoptosis in a Rat Model of Sepsis. Intensive Care Med. Exp. 5, 1

    Not in our library10.1186/s40635-016-0114-1

  62. 62.

    Esen F. Senturk E. Ozcan P. E. Ahishali B. Arican N. Orhan N.. (2012 ). Intravenous Immunoglobulins Prevent the Breakdown of the Blood-Brain Barrier in Experimentally Induced Sepsis. Crit. Care Med. 40, 1214–1220

    Not in our library10.1097/ccm.0b013e31823779ca

  63. 63.
  64. 64.

    Fleischmann C. Scherag A. Adhikari N. K. Hartog C. S. Tsaganos T. Schlattmann P.. (2016 a). Assessment of Global Incidence and Mortality of Hospital-Treated Sepsis. Current Estimates and Limitations. Am. J. Respir. Crit. Care Med. 193, 259–272

    Not in our library10.1164/rccm.201504-0781oc

  65. 65.

    Fleischmann C. Thomas-Rueddel D. O. Hartmann M. Hartog C. S. Welte T. Heublein S.. (2016 b). Hospital Incidence and Mortality Rates of Sepsis. Dtsch Arztebl Int. 113, 159–166

    Not in our library10.3238/arztebl.2016.0159

  66. 66.

    Flierl M. A. Stahel P. F. Rittirsch D. Huber-Lang M. Niederbichler A. D. Hoesel L. M.. (2009 ). Inhibition of Complement C5a Prevents Breakdown of the Blood-Brain Barrier and Pituitary Dysfunction in Experimental Sepsis. Crit. Care 13, R12

    Not in our library10.1186/cc7710

  67. 67.

    Forster C. (2008 ). Tight Junctions and the Modulation of Barrier Function in Disease. Histochem Cell Biol. 130, 55–70

    Not in our library10.1007/s00418-008-0424-9

  68. 68.

    Frister A. Schmidt C. Schneble N. Brodhun M. Gonnert F. A. Bauer M.. (2014 ). Phosphoinositide 3-Kinase Gamma Affects LPS-Induced Disturbance of Blood-Brain Barrier via Lipid Kinase-Independent Control of cAMP in Microglial Cells. Neuromolecular Med. 16, 704–713

    Not in our library10.1007/s12017-014-8320-z

  69. 69.

    Fritz M. Klawonn A. M. Jaarola M. Engblom D. (2018 ). Interferon- Mediated Signaling in the Brain Endothelium Is Critical for Inflammation-Induced Aversion. Brain Behav. Immun. 67, 54–58

    Not in our library10.1016/j.bbi.2017.08.020

  70. 70.

    Gadre S. K. Shah M. Mireles-Cabodevila E. Patel B. Duggal A. (2019 ). Epidemiology and Predictors of 30-Day Readmission in Patients With Sepsis. Chest 155, 483–490

    Not in our library10.1016/j.chest.2018.12.008

  71. 71.

    Gao H. M. Hong J. S. (2008 ). Why Neurodegenerative Diseases Are Progressive: Uncontrolled Inflammation Drives Disease Progression. Trends Immunol. 29, 357–365

    Not in our library10.1016/j.it.2008.05.002

  72. 72.

    Goeritzer M. Bernhart E. Plastira I. Reicher H. Leopold C. Eichmann T. O.. (2020 ). Myeloperoxidase and Septic Conditions Disrupt Sphingolipid Homeostasis in Murine Brain Capillaries In Vivo and Immortalized Human Brain Endothelial Cells In Vitro. Int. J. Mol. Sci. 21, 1143

    Not in our library10.3390/ijms21031143

  73. 73.

    Gofton T. E. Young G. B. (2012 ). Sepsis-Associated Encephalopathy. Nat. Rev. Neurol. 8, 557–566

    Not in our library10.1038/nrneurol.2012.183

  74. 74.

    Golzari S. E. Mahmoodpoor A. (2014 ). Sepsis-Associated Encephalopathy Versus Sepsis-Induced Encephalopathy. Lancet Neurol. 13, 967–968

    Not in our library10.1016/s1474-4422(14)70205-4

  75. 75.

    Greenhalgh A. D. David S. Bennett F. C. (2020 ). Immune Cell Regulation of Glia During CNS Injury and Disease. Nat. Rev. Neurosci. 21, 139–152

    Not in our library10.1038/s41583-020-0263-9

  76. 76.

    Griton M. Dhaya I. Nicolas R. Raffard G. Periot O. Hiba B.. (2020 ). Experimental Sepsis-Associated Encephalopathy Is Accompanied by Altered Cerebral Blood Perfusion and Water Diffusion and Related to Changes in Cyclooxygenase-2 Expression and Glial Cell Morphology But Not to Blood-Brain Barrier Breakdown. Brain Behav. Immun. 83, 200–213

    Not in our library10.1016/j.bbi.2019.10.012

  77. 77.
  78. 78.

    Hamano N. Nishi K. Onose A. Okamoto A. Umegaki T. Yamazaki E.. (2013 ). Efficacy of Single-Dose Intravenous Immunoglobulin Administration for Severe Sepsis and Septic Shock. J. Intensive Care 1, 4

    Not in our library10.1186/2052-0492-1-4

  79. 79.

    Hao H. Cao L. Jiang C. Che Y. Zhang S. Takahashi S.. (2017 ). Farnesoid X Receptor Regulation of the NLRP3 Inflammasome Underlies Cholestasis-Associated Sepsis. Cell Metab. 25, 856–867.e855

    Not in our library10.1016/j.cmet.2017.03.007

  80. 80.

    Hartz A. M. Bauer B. Fricker G. Miller D. S. (2006 ). Rapid Modulation of P-Glycoprotein-Mediated Transport at the Blood-Brain Barrier by Tumor Necrosis Factor-Alpha and Lipopolysaccharide. Mol. Pharmacol. 69, 462–470

    Not in our library10.1124/mol.105.017954

  81. 81.
  82. 82.

    Haseloff R. F. Dithmer S. Winkler L. Wolburg H. Blasig I. E. (2015 ). Transmembrane Proteins of the Tight Junctions at the Blood-Brain Barrier: Structural and Functional Aspects. Semin. Cell Dev. Biol. 38, 16–25

    Not in our library10.1016/j.semcdb.2014.11.004

  83. 83.

    Hawkins B. T. Davis T. P. (2005 ). The Blood-Brain Barrier/Neurovascular Unit in Health and Disease. Pharmacol. Rev. 57, 173–185

    Not in our library10.1124/pr.57.2.4

  84. 84.

    He F. Peng J. Deng X. L. Yang L. F. Wu L. W. Zhang C. L.. (2011 ). RhoA and NF-kappaB Are Involved in Lipopolysaccharide-Induced Brain Microvascular Cell Line Hyperpermeability. Neuroscience 188, 35–47

    Not in our library10.1016/j.neuroscience.2011.04.025

  85. 85.

    Hernandes M. S. D’Avila J. C. Trevelin S. C. Reis P. A. Kinjo E. R. Lopes L. R.. (2014 ). The Role of Nox2-Derived ROS in the Development of Cognitive Impairment After Sepsis. J. Neuroinflamm. 11, 36

    Not in our library10.1186/1742-2094-11-36

  86. 86.

    Hong S. Park K. K. Magae J. Ando K. Lee T. S. Kwon T. K.. (2005 ). Ascochlorin Inhibits Matrix Metalloproteinase-9 Expression by Suppressing Activator Protein-1-Mediated Gene Expression Through the ERK1/2 Signaling Pathway: Inhibitory Effects of Ascochlorin on the Invasion of Renal Carcinoma Cells. J. Biol. Chem. 280, 25202–25209

    Not in our library10.1074/jbc.m413985200

  87. 87.

    Huang C. T. Lue J. H. Cheng T. H. Tsai Y. J. (2020 a). Glycemic Control With Insulin Attenuates Sepsis-Associated Encephalopathy by Inhibiting Glial Activation via the Suppression of the Nuclear Factor Kappa B and Mitogen-Activated Protein Kinase Signaling Pathways in Septic Rats. Brain Res. 1738, 146822

    Not in our library10.1016/j.brainres.2020.146822

  88. 88.
  89. 89.
  90. 90.

    Hu Y. Huang M. Wang P. Xu Q. Zhang B. (2013 ). Ucf-101 Protects Against Cerebral Oxidative Injury and Cognitive Impairment in Septic Rat. Int. Immunopharmacol. 16, 108–113

    Not in our library10.1016/j.intimp.2013.03.019

  91. 91.

    Hu J. Vacas S. Feng X. Lutrin D. Uchida Y. Lai I. K.. (2018 ). Dexmedetomidine Prevents Cognitive Decline by Enhancing Resolution of High Mobility Group Box 1 Protein-Induced Inflammation Through a Vagomimetic Action in Mice. Anesthesiology 128, 921–931

    Not in our library10.1097/aln.0000000000002038

  92. 92.

    Hu Y. Wang Z. Pan S. Zhang H. Fang M. Jiang H.. (2017 ). Melatonin Protects Against Blood-Brain Barrier Damage by Inhibiting the TLR4/ NF-kappaB Signaling Pathway After LPS Treatment in Neonatal Rats. Oncotarget 8, 31638–31654

    Not in our library10.18632/oncotarget.15780

  93. 93.

    Hyeon S. Lee H. Yang Y. Jeong W. (2013 ). Nrf2 Deficiency Induces Oxidative Stress and Promotes RANKL-Induced Osteoclast Differentiation. Free Radic. Biol. Med. 65, 789–799

    Not in our library10.1016/j.freeradbiomed.2013.08.005

  94. 94.

    Iliff J. J. Jia J. Nelson J. Goyagi T. Klaus J. Alkayed N. J. (2010 ). Epoxyeicosanoid Signaling in CNS Function and Disease. Prostaglandins Other Lipid Mediat. 91, 68–84

    Not in our library10.1016/j.prostaglandins.2009.06.004

  95. 95.

    Imamura Y. Wang H. Matsumoto N. Muroya T. Shimazaki J. Ogura H.. (2011 ). Interleukin-1beta Causes Long-Term Potentiation Deficiency in a Mouse Model of Septic Encephalopathy. Neuroscience 187, 63–69

    Not in our library10.1016/j.neuroscience.2011.04.063

  96. 96.

    Islam M. T. Bardaweel S. K. Mubarak M. S. Koch W. Gawel-Beben K. Antosiewicz B.. (2020 ). Immunomodulatory Effects of Diterpenes and Their Derivatives Through NLRP3 Inflammasome Pathway: A Review. Front. Immunol. 11, 572136

    Not in our library10.3389/fimmu.2020.572136

  97. 97.

    Ismail Hassan F. Didari T. Baeeri M. Gholami M. Haghi-Aminjan H. Khalid M.. (2020 ). Metformin Attenuates Brain Injury by Inhibiting Inflammation and Regulating Tight Junction Proteins in Septic Rats. Cell J. 22, 29–37

    Not in our library10.22074/cellj.2020.7046

  98. 98.

    Iwashyna T. J. Cooke C. R. Wunsch H. Kahn J. M. (2012 ). Population Burden of Long-Term Survivorship After Severe Sepsis in Older Americans. J. Am. Geriatr. Soc 60, 1070–1077

    Not in our library10.1111/j.1532-5415.2012.03989.x

  99. 99.

    Iwashyna T. J. Ely E. W. Smith D. M. Langa K. M. (2010 ). Long-Term Cognitive Impairment and Functional Disability Among Survivors of Severe Sepsis. JAMA 304, 1787–1794

    Not in our library10.1001/jama.2010.1553

  100. 100.

    Jarczak D. Kluge S. Nierhaus A. (2020 ). Use of Intravenous Immunoglobulins in Sepsis Therapy-A Clinical View. Int. J. Mol. Sci. 21, 5543

    Not in our library10.3390/ijms21155543

  101. 101.

    Jesus A. A. Passaglia P. Santos B. M. Rodrigues-Santos I. Flores R. A. Batalhao M. E.. (2020 ). Chronic Molecular Hydrogen Inhalation Mitigates Short and Long-Term Memory Loss in Polymicrobial Sepsis. Brain Res. 1739, 146857

    Not in our library10.1016/j.brainres.2020.146857

  102. 102.

    Jones S. A. Dewald B. Clark-Lewis I. Baggiolini M. (1997 ). Chemokine Antagonists That Discriminate Between Interleukin-8 Receptors. Selective Blockers of CXCR2. J. Biol. Chem. 272, 16166–16169

    Not in our library10.1074/jbc.272.26.16166

  103. 103.

    Kaplan L. Chow B. W. Gu C. (2020 ). Neuronal Regulation of the Blood-Brain Barrier and Neurovascular Coupling. Nat. Rev. Neurosci. 21, 416–432

    Not in our library10.1038/s41583-020-0322-2

  104. 104.

    Keaney J. Campbell M. (2015 ). The Dynamic Blood-Brain Barrier. FEBS J. 282, 4067–4079

    Not in our library10.1111/febs.13412

  105. 105.

    Kikuchi D. S. Campos A. C. P. Qu H. Forrester S. J. Pagano R. L. Lassegue B.. (2019 ). Poldip2 Mediates Blood-Brain Barrier Disruption in a Model of Sepsis-Associated Encephalopathy. J. Neuroinflammation. 16, 241

    Not in our library10.1186/s12974-019-1575-4

  106. 106.

    Kingsley S. M. Bhat B. V. (2016 ). Differential Paradigms in Animal Models of Sepsis. Curr. Infect. Dis. Rep. 18, 26

    Not in our library10.1007/s11908-016-0535-8

  107. 107.
  108. 108.

    Kuperberg S. J. Wadgaonkar R. (2017 ). Sepsis-Associated Encephalopathy: The Blood-Brain Barrier and the Sphingolipid Rheostat. Front. Immunol. 8, 597

    Not in our library10.3389/fimmu.2017.00597

  109. 109.

    Kutuzov N. Flyvbjerg H. Lauritzen M. (2018 ). Contributions of the Glycocalyx, Endothelium, and Extravascular Compartment to the Blood-Brain Barrier. Proc. Natl. Acad. Sci. U. S. A. 115, E9429–E9438

    Not in our library10.1073/pnas.1802155115

  110. 110.

    Langen U. H. Ayloo S. Gu C. (2019 ). Development and Cell Biology of the Blood-Brain Barrier. Annu. Rev. Cell Dev. Biol. 35, 591–613

    Not in our library10.1146/annurev-cellbio-100617-062608

  111. 111.

    Lee S. W. Jung K. H. Jeong C. H. Seo J. H. Yoon D. K. Suh J. K.. (2011 ). Inhibition of Endothelial Cell Migration Through the Downregulation of MMP-9 by A-Kinase Anchoring Protein 12. Mol. Med. Rep. 4, 145–149

    Not in our library10.3892/mmr.2010.389

  112. 112.

    Lelubre C. Vincent J. L. (2018 ). Mechanisms and Treatment of Organ Failure in Sepsis. Nat. Rev. Nephrol. 14, 417–427

    Not in our library10.1038/s41581-018-0005-7

  113. 113.
  114. 114.

    Linden J. R. Flores C. Schmidt E. F. Uzal F. A. Michel A. O. Valenzuela M.. (2019 ). Clostridium Perfringens Epsilon Toxin Induces Blood Brain Barrier Permeability via Caveolae-Dependent Transcytosis and Requires Expression of MAL. PloS Pathog. 15, e1008014

    Not in our library10.1371/journal.ppat.1008014

  115. 115.

    Linville R. M. DeStefano J. G. Sklar M. B. Xu Z. Farrell A. M. Bogorad M. I.. (2019 ). Human iPSC-Derived Blood-Brain Barrier Microvessels: Validation of Barrier Function and Endothelial Cell Behavior. Biomaterials 190–191, 24–37

    Not in our library10.1016/j.biomaterials.2018.10.023

  116. 116.

    Liu H. Davis J. R. Wu Z. L. Faez Abdelgawad A. (2017 ). Dexmedetomidine Attenuates Lipopolysaccharide Induced MCP-1 Expression in Primary Astrocyte. BioMed. Res. Int. 2017, 6352159

    Not in our library10.1155/2017/6352159

  117. 117.

    Liu W. Y. Wang Z. B. Wang Y. Tong L. C. Li Y. Wei X.. (2015 ). Increasing the Permeability of the Blood-Brain Barrier in Three Different Models In Vivo. CNS Neurosci. Ther. 21, 568–574

    Not in our library10.1111/cns.12405

  118. 118.

    Liu L. Zhang H. Shi Y. Pan L. (2020 ). Prostaglandin E1 Improves Cerebral Microcirculation Through Activation of Endothelial NOS and GRPCH1. J. Mol. Neurosci. 70, 2041–2048

    Not in our library10.1007/s12031-020-01610-y

  119. 119.

    Li H. Wang P. Huang F. Jin J. Wu H. Zhang B.. (2018 ). Astragaloside IV Protects Blood-Brain Barrier Integrity From LPS-Induced Disruption via Activating Nrf2 Antioxidant Signaling Pathway in Mice. Toxicol. Appl. Pharmacol. 340, 58–66

    Not in our library10.1016/j.taap.2017.12.019

  120. 120.

    Li C. C. Yang H. T. Hou Y. C. Chiu Y. S. Chiu W. C. (2014 ). Dietary Fish Oil Reduces Systemic Inflammation and Ameliorates Sepsis-Induced Liver Injury by Up-Regulating the Peroxisome Proliferator-Activated Receptor Gamma-Mediated Pathway in Septic Mice. J. Nutr. Biochem. 25, 19–25

    Not in our library10.1016/j.jnutbio.2013.08.010

  121. 121.

    Li T. Zheng L. N. Han X. H. (2020 ). Fenretinide Attenuates Lipopolysaccharide (LPS)-Induced Blood-Brain Barrier (BBB) and Depressive-Like Behavior in Mice by Targeting Nrf-2 Signaling. BioMed. Pharmacother. 125, 109680

    Not in our library10.1016/j.biopha.2019.109680

  122. 122.

    Loscher W. Gericke B. (2020 ). Novel Intrinsic Mechanisms of Active Drug Extrusion at the Blood-Brain Barrier: Potential Targets for Enhancing Drug Delivery to the Brain? Pharmaceutics 12, 966

    Not in our library10.3390/pharmaceutics12100966

  123. 123.

    Lottes R. G. Newton D. A. Spyropoulos D. D. Baatz J. E. (2015 ). Lactate as Substrate for Mitochondrial Respiration in Alveolar Epithelial Type II Cells. Am. J. Physiol. Lung Cell Mol. Physiol. 308, L953–L961

    Not in our library10.1152/ajplung.00335.2014

  124. 124.

    Lou S. Lepak V. C. Eberly L. E. Roth B. Cui W. Zhu X. H.. (2016 ). Oxygen Consumption Deficit in Huntington Disease Mouse Brain Under Metabolic Stress. Hum. Mol. Genet. 25, 2813–2826

    Not in our library10.1093/hmg/ddw138

  125. 125.

    Lu M. C. Ji J. A. Jiang Z. Y. You Q. D. (2016 ). The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update. Med. Res. Rev. 36, 924–963

    Not in our library10.1002/med.21396

  126. 126.

    Mae M. Armulik A. Betsholtz C. (2011 ). Getting to Know the Cast - Cellular Interactions and Signaling at the Neurovascular Unit. Curr. Pharm. Des. 17, 2750–2754

    Not in our library10.2174/138161211797440113

  127. 127.

    Malinsky R. R. Valera F. C. Cavallari F. E. Kupper D. S. Milaneze C. Silva J. S.. (2013 ). Matrix Metalloproteinases and Their Impact on Sinusal Extension in Chronic Rhinosinusitis With Nasal Polyps. Eur. Arch. Otorhinolaryngol. 270, 1345–1348

    Not in our library10.1007/s00405-012-2219-9

  128. 128.

    Margotti W. Giustina A. D. de Souza Goldim M. P. Hubner M. Cidreira T. Denicol T. L.. (2020 ). Aging Influences in the Blood-Brain Barrier Permeability and Cerebral Oxidative Stress in Sepsis. Exp. Gerontol. 140, 111063

    Not in our library10.1016/j.exger.2020.111063

  129. 129.

    Matsumoto J. Dohgu S. Takata F. Nishioku T. Sumi N. Machida T.. (2012 ). Lipopolysaccharide-Activated Microglia Lower P-Glycoprotein Function in Brain Microvascular Endothelial Cells. Neurosci. Lett. 524, 45–48

    Not in our library10.1016/j.neulet.2012.07.004

  130. 130.
  131. 131.

    Mei B. Li J. Zuo Z. (2021 ). Dexmedetomidine Attenuates Sepsis-Associated Inflammation and Encephalopathy via Central Alpha2a Adrenoceptor. Brain Behav. Immun. 91, 296–314

    Not in our library10.1016/j.bbi.2020.10.008

  132. 132.

    Miao F. Shan C. Shah S. A. H. Akhtar R. W. Geng S. Ning D.. (2021 ). The Protective Effect of Walnut Oil on Lipopolysaccharide-Induced Acute Intestinal Injury in Mice. Food Sci. Nutr. 9, 711–718

    Not in our library10.1002/fsn3.2035

  133. 133.

    Michels M. Danieslki L. G. Vieira A. Florentino D. Dall’Igna D. Galant L.. (2015 a). CD40-CD40 Ligand Pathway Is a Major Component of Acute Neuroinflammation and Contributes to Long-Term Cognitive Dysfunction After Sepsis. Mol. Med. 21, 219–226

    Not in our library10.2119/molmed.2015.00070

  134. 134.

    Michels M. Vieira A. S. Vuolo F. Zapelini H. G. Mendonca B. Mina F.. (2015 b). The Role of Microglia Activation in the Development of Sepsis-Induced Long-Term Cognitive Impairment. Brain Behav. Immun. 43, 54–59

    Not in our library10.1016/j.bbi.2014.07.002

  135. 135.

    Miller A. A. Drummond G. R. De Silva T. M. Mast A. E. Hickey H. Williams J. P.. (2009 ). NADPH Oxidase Activity Is Higher in Cerebral Versus Systemic Arteries of Four Animal Species: Role of Nox2. Am. J. Physiol. Heart Circ. Physiol. 296, H220–H225

    Not in our library10.1152/ajpheart.00987.2008

  136. 136.

    Mina F. Comim C. M. Dominguini D. Cassol O. J. Jr. Dall Igna D. M. Ferreira G. K.. (2014 ). Il1-Beta Involvement in Cognitive Impairment After Sepsis. Mol. Neurobiol. 49, 1069–1076

    Not in our library10.1007/s12035-013-8581-9

  137. 137.

    Nayak D. Huo Y. Kwang W. X. Pushparaj P. N. Kumar S. D. Ling E. A.. (2010 ). Sphingosine Kinase 1 Regulates the Expression of Proinflammatory Cytokines and Nitric Oxide in Activated Microglia. Neuroscience 166, 132–144

    Not in our library10.1016/j.neuroscience.2009.12.020

  138. 138.

    Nikolakopoulou A. M. Montagne A. Kisler K. Dai Z. Wang Y. Huuskonen M. T.. (2019 ). Pericyte Loss Leads to Circulatory Failure and Pleiotrophin Depletion Causing Neuron Loss. Nat. Neurosci. 22, 1089–1098

    Not in our library10.1038/s41593-019-0434-z

  139. 139.

    Nishioku T. Dohgu S. Takata F. Eto T. Ishikawa N. Kodama K. B.. (2009 ). Detachment of Brain Pericytes From the Basal Lamina Is Involved in Disruption of the Blood-Brain Barrier Caused by Lipopolysaccharide-Induced Sepsis in Mice. Cell Mol. Neurobiol. 29, 309–316

    Not in our library10.1007/s10571-008-9322-x

  140. 140.

    Nishioku T. Matsumoto J. Dohgu S. Sumi N. Miyao K. Takata F.. (2010 ). Tumor Necrosis Factor-Alpha Mediates the Blood-Brain Barrier Dysfunction Induced by Activated Microglia in Mouse Brain Microvascular Endothelial Cells. J. Pharmacol. Sci. 112, 251–254

    Not in our library10.1254/jphs.09292sc

  141. 141.

    Nwafor D. C. Brichacek A. L. Mohammad A. S. Griffith J. Lucke-Wold B. P. Benkovic S. A.. (2019 ). Targeting the Blood-Brain Barrier to Prevent Sepsis-Associated Cognitive Impairment. J. Cent Nerv Syst. Dis. 11, 1179573519840652

    Not in our library10.1177/1179573519840652

  142. 142.

    Obermeier B. Daneman R. Ransohoff R. M. (2013 ). Development, Maintenance and Disruption of the Blood-Brain Barrier. Nat. Med. 19, 1584–1596

    Not in our library10.1038/nm.3407

  143. 143.

    Opal S. M. (2010 ). Endotoxins and Other Sepsis Triggers. Contrib Nephrol. 167, 14–24

    Not in our library10.1159/000315915

  144. 144.

    Pan W. Yu C. Hsuchou H. Kastin A. J. (2010 ). The Role of Cerebral Vascular NFkappaB in LPS-Induced Inflammation: Differential Regulation of Efflux Transporter and Transporting Cytokine Receptors. Cell Physiol. Biochem. 25, 623–630

    Not in our library10.1159/000315081

  145. 145.

    Park H. J. Shin J. Y. Kim H. N. Oh S. H. Song S. K. Lee P. H. (2015 ). Mesenchymal Stem Cells Stabilize the Blood-Brain Barrier Through Regulation of Astrocytes. Stem Cell Res. Ther. 6, 187

    Not in our library10.1186/s13287-015-0180-4

  146. 146.

    Patel M. (2016 ). Targeting Oxidative Stress in Central Nervous System Disorders. Trends Pharmacol. Sci. 37, 768–778

    Not in our library10.1016/j.tips.2016.06.007

  147. 147.

    Poston J. T. Koyner J. L. (2019 ). Sepsis Associated Acute Kidney Injury. BMJ 364, k4891

    Not in our library10.1136/bmj.k4891

  148. 148.

    Prinz M. Priller J. (2017 ). The Role of Peripheral Immune Cells in the CNS in Steady State and Disease. Nat. Neurosci. 20, 136–144

    Not in our library10.1038/nn.4475

  149. 149.

    Qin L. H. Huang W. Mo X. A. Chen Y. L. Wu X. H. (2015 ). LPS Induces Occludin Dysregulation in Cerebral Microvascular Endothelial Cells via MAPK Signaling and Augmenting MMP-2 Levels. Oxid. Med. Cell Longev. 2015, 120641

    Not in our library10.1155/2015/120641

  150. 150.

    Ren C. Li N. Wang B. Yang Y. Gao J. Li S.. (2015 ). Limb Ischemic Perconditioning Attenuates Blood-Brain Barrier Disruption by Inhibiting Activity of MMP-9 and Occludin Degradation After Focal Cerebral Ischemia. Aging Dis. 6, 406–417

    Not in our library10.14336/ad.2015.0812

  151. 151.
  152. 152.

    Rios-Santos F. Alves-Filho J. C. Souto F. O. Spiller F. Freitas A. Lotufo C. M.. (2007 ). Down-Regulation of CXCR2 on Neutrophils in Severe Sepsis Is Mediated by Inducible Nitric Oxide Synthase-Derived Nitric Oxide. Am. J. Respir. Crit. Care Med. 175, 490–497

    Not in our library10.1164/rccm.200601-103oc

  153. 153.

    Ronaldson P. T. Davis T. P. (2020 ). Regulation of Blood-Brain Barrier Integrity by Microglia in Health and Disease: A Therapeutic Opportunity. J. Cereb Blood Flow Metab. 40, S6–S24

    Not in our library10.1177/0271678x20951995

  154. 154.

    Sadeghian H. Lacoste B. Qin T. Toussay X. Rosa R. Oka F.. (2018 ). Spreading Depolarizations Trigger Caveolin-1-Dependent Endothelial Transcytosis. Ann. Neurol. 84, 409–423

    Not in our library10.1002/ana.25298

  155. 155.

    Salkeni M. A. Lynch J. L. Otamis-Price T. Banks W. A. (2009 ). Lipopolysaccharide Impairs Blood-Brain Barrier P-Glycoprotein Function in Mice Through Prostaglandin- and Nitric Oxide-Independent Pathways. J. Neuroimmune Pharmacol. 4, 276–282

    Not in our library10.1007/s11481-008-9138-y

  156. 156.

    Savio L. E. B. de Andrade Mello P. Figliuolo V. R. de Avelar Almeida T. F. Santana P. T. Oliveira S. D. S.. (2017 ). CD39 Limits P2X7 Receptor Inflammatory Signaling and Attenuates Sepsis-Induced Liver Injury. J. Hepatol. 67, 716–726

    Not in our library10.1016/j.jhep.2017.05.021

  157. 157.

    Schreibelt G. Kooij G. Reijerkerk A. van Doorn R. Gringhuis S. I. van der Pol S.. (2007 ). Reactive Oxygen Species Alter Brain Endothelial Tight Junction Dynamics via RhoA, PI3 Kinase, and PKB Signaling. FASEB J. 21, 3666–3676

    Not in our library10.1096/fj.07-8329com

  158. 158.

    Semmler A. Okulla T. Sastre M. Dumitrescu-Ozimek L. Heneka M. T. (2005 ). Systemic Inflammation Induces Apoptosis With Variable Vulnerability of Different Brain Regions. J. Chem. Neuroanat. 30, 144–157

    Not in our library10.1016/j.jchemneu.2005.07.003

  159. 159.

    Seok S. M. Kim J. M. Park T. Y. Baik E. J. Lee S. H. (2013 ). Fructose-1,6-Bisphosphate Ameliorates Lipopolysaccharide-Induced Dysfunction of Blood-Brain Barrier. Arch. Pharm. Res. 36, 1149–1159

    Not in our library10.1007/s12272-013-0129-z

  160. 160.

    Sharshar T. Carlier R. Bernard F. Guidoux C. Brouland J. P. Nardi O.. (2007 ). Brain Lesions in Septic Shock: A Magnetic Resonance Imaging Study. Intensive Care Med. 33, 798–806

    Not in our library10.1007/s00134-007-0598-y

  161. 161.

    Shoji A. Kabeya M. Ishida Y. Yanagida A. Shibusawa Y. Sugawara M. (2014 ). Evaluation of cathepsin B activity for degrading collagen IV using a surface plasmon resonance method and circular dichroism spectroscopy. J. Pharm. BioMed. Anal. 95, 47–53

    Not in our library10.1016/j.jpba.2014.02.009

  162. 162.

    Silva A. Y. O. Amorim E. A. Barbosa-Silva M. C. Lima M. N. Oliveira H. A. Granja M. G.. (2020 ). Mesenchymal Stromal Cells Protect the Blood-Brain Barrier, Reduce Astrogliosis, and Prevent Cognitive and Behavioral Alterations in Surviving Septic Mice. Crit. Care Med. 48, e290–e298

    Not in our library10.1097/ccm.0000000000004219

  163. 163.

    Silwedel C. Speer C. P. Haarmann A. Fehrholz M. Claus H. Buttmann M.. (2018 ). Novel Insights Into Neuroinflammation: Bacterial Lipopolysaccharide, Tumor Necrosis Factor Alpha, and Ureaplasma Species Differentially Modulate Atypical Chemokine Receptor 3 Responses in Human Brain Microvascular Endothelial Cells. J. Neuroinflammation. 15, 156

    Not in our library10.1186/s12974-018-1170-0

  164. 164.

    Singer M. Deutschman C. S. Seymour C. W. Shankar-Hari M. Annane D. Bauer M.. (2016 ). The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315, 801–810

    Not in our library10.1001/jama.2016.0287

  165. 165.

    Sivandzade F. Alqahtani F. Sifat A. Cucullo L. (2020 ). The Cerebrovascular and Neurological Impact of Chronic Smoking on Post-Traumatic Brain Injury Outcome and Recovery: An In Vivo Study. J. Neuroinflamm. 17, 133

    Not in our library10.1186/s12974-020-01818-0

  166. 166.

    Skirecki T. Cavaillon J. M. (2019 ). Inner Sensors of Endotoxin - Implications for Sepsis Research and Therapy. FEMS Microbiol. Rev. 43, 239–256

    Not in our library10.1093/femsre/fuz004

  167. 167.
  168. 168.
  169. 169.

    Spampinato S. F. Bortolotto V. Canonico P. L. Sortino M. A. Grilli M. (2019 ). Astrocyte-Derived Paracrine Signals: Relevance for Neurogenic Niche Regulation and Blood-Brain Barrier Integrity. Front. Pharmacol. 10, 1346

    Not in our library10.3389/fphar.2019.01346

  170. 170.

    Stapor P. Wang X. Goveia J. Moens S. Carmeliet P. (2014 ). Angiogenesis Revisited - Role and Therapeutic Potential of Targeting Endothelial Metabolism. J. Cell Sci. 127, 4331–4341

    Not in our library10.1242/jcs.153908

  171. 171.

    Su L. Lei X. Ma H. Feng C. Jiang J. Jiao J. (2020 ). PRDM16 Orchestrates Angiogenesis via Neural Differentiation in the Developing Brain. Cell Death Differ. 27, 2313–2329

    Not in our library10.1038/s41418-020-0504-5

  172. 172.

    Suliman H. B. Carraway M. S. Welty-Wolf K. E. Whorton A. R. Piantadosi C. A. (2003 ). Lipopolysaccharide Stimulates Mitochondrial Biogenesis via Activation of Nuclear Respiratory Factor-1. J. Biol. Chem. 278, 41510–41518

    Not in our library10.1074/jbc.m304719200

  173. 173.

    Sumi N. Nishioku T. Takata F. Matsumoto J. Watanabe T. Shuto H.. (2010 ). Lipopolysaccharide-Activated Microglia Induce Dysfunction of the Blood-Brain Barrier in Rat Microvascular Endothelial Cells Co-Cultured With Microglia. Cell Mol. Neurobiol. 30, 247–253

    Not in our library10.1007/s10571-009-9446-7

  174. 174.

    Sun Y. Yao X. Zhang Q. J. Zhu M. Liu Z. P. Ci B.. (2018 ). Beclin-1-Dependent Autophagy Protects the Heart During Sepsis. Circulation 138, 2247–2262

    Not in our library10.1161/circulationaha.117.032821

  175. 175.

    Sweeney M. D. Ayyadurai S. Zlokovic B. V. (2016 ). Pericytes of the Neurovascular Unit: Key Functions and Signaling Pathways. Nat. Neurosci. 19, 771–783

    Not in our library10.1038/nn.4288

  176. 176.

    Sweeney M. D. Zhao Z. Montagne A. Nelson A. R. Zlokovic B. V. (2019 ). Blood-Brain Barrier: From Physiology to Disease and Back. Physiol. Rev. 99, 21–78

    Not in our library10.1152/physrev.00050.2017

  177. 177.

    Szakmany T. (2019 ). Intravenous Immunoglobulin in Sepsis: Can We Find the Right Dose? Minerva Anestesiol. 85, 115–117

    Not in our library10.23736/s0375-9393.18.13349-9

  178. 178.

    Taile J. Arcambal A. Clerc P. Gauvin-Bialecki A. Gonthier M. P. (2020 ). Medicinal Plant Polyphenols Attenuate Oxidative Stress and Improve Inflammatory and Vasoactive Markers in Cerebral Endothelial Cells During Hyperglycemic Condition. Antioxidants (Basel). 9, 573

    Not in our library10.3390/antiox9070573

  179. 179.

    Takata F. Dohgu S. Matsumoto J. Machida T. Kaneshima S. Matsuo M.. (2013 ). Metformin Induces Up-Regulation of Blood-Brain Barrier Functions by Activating AMP-Activated Protein Kinase in Rat Brain Microvascular Endothelial Cells. Biochem. Biophys. Res. Commun. 433, 586–590

    Not in our library10.1016/j.bbrc.2013.03.036

  180. 180.

    Tam S. J. Watts R. J. (2010 ). Connecting Vascular and Nervous System Development: Angiogenesis and the Blood-Brain Barrier. Annu. Rev. Neurosci. 33, 379–408

    Not in our library10.1146/annurev-neuro-060909-152829

  181. 181.
  182. 182.
  183. 183.

    Tarassishin L. Suh H. S. Lee S. C. (2014 ). LPS and IL-1 Differentially Activate Mouse and Human Astrocytes: Role of CD14. Glia 62, 999–1013

    Not in our library10.1002/glia.22657

  184. 184.

    Tauber S. C. Eiffert H. Bruck W. Nau R. (2017 ). Septic Encephalopathy and Septic Encephalitis. Expert Rev. Anti Infect. Ther. 15, 121–132

    Not in our library10.1080/14787210.2017.1265448

  185. 185.

    Tietz S. Engelhardt B. (2015 ). Brain Barriers: Crosstalk Between Complex Tight Junctions and Adherens Junctions. J. Cell Biol. 209, 493–506

    Not in our library10.1083/jcb.201412147

  186. 186.

    Tilling T. Korte D. Hoheisel D. Galla H. J. (1998 ). Basement Membrane Proteins Influence Brain Capillary Endothelial Barrier Function In Vitro. J. Neurochem. 71, 1151–1157

    Not in our library10.1046/j.1471-4159.1998.71031151.x

  187. 187.

    Tiruppathi C. Shimizu J. Miyawaki-Shimizu K. Vogel S. M. Bair A. M. Minshall R. D.. (2008 ). Role of NF-kappaB-Dependent Caveolin-1 Expression in the Mechanism of Increased Endothelial Permeability Induced by Lipopolysaccharide. J. Biol. Chem. 283, 4210–4218

    Not in our library10.1074/jbc.m703153200

  188. 188.

    Tsai Y. L. Coady T. H. Lu L. Zheng D. Alland I. Tian B.. (2020 ). ALS/FTD-Associated Protein FUS Induces Mitochondrial Dysfunction by Preferentially Sequestering Respiratory Chain Complex mRNAs. Genes Dev. 34, 785–805

    Not in our library10.1101/gad.335836.119

  189. 189.

    Ugun-Klusek A. Tatham M. H. Elkharaz J. Constantin-Teodosiu D. Lawler K. Mohamed H.. (2017 ). Continued 26S Proteasome Dysfunction in Mouse Brain Cortical Neurons Impairs Autophagy and the Keap1-Nrf2 Oxidative Defence Pathway. Cell Death Dis. 8, e2531

    Not in our library10.1038/cddis.2016.443

  190. 190.

    Ullen A. Singewald E. Konya V. Fauler G. Reicher H. Nusshold C.. (2013 ). Myeloperoxidase-Derived Oxidants Induce Blood-Brain Barrier Dysfunction In Vitro and In Vivo. PloS One 8, e64034

    Not in our library10.1371/journal.pone.0064034

  191. 191.

    Vanlaere I. Libert C. (2009 ). Matrix Metalloproteinases as Drug Targets in Infections Caused by Gram-Negative Bacteria and in Septic Shock. Clin. Microbiol. Rev. 22, 224–239

    Not in our library10.1128/cmr.00047-08

  192. 192.

    Varatharaj A. Galea I. (2017 ). The Blood-Brain Barrier in Systemic Inflammation. Brain Behav. Immun. 60, 1–12

    Not in our library10.1016/j.bbi.2016.03.010

  193. 193.

    Verstrepen L. Bekaert T. Chau T. L. Tavernier J. Chariot A. Beyaert R. (2008 ). TLR-4, IL-1R and TNF-R Signaling to NF-Kappab: Variations on a Common Theme. Cell Mol. Life Sci. 65, 2964–2978

    Not in our library10.1007/s00018-008-8064-8

  194. 194.

    Veszelka S. Pasztoi M. Farkas A. E. Krizbai I. Ngo T. K. Niwa M.. (2007 ). Pentosan Polysulfate Protects Brain Endothelial Cells Against Bacterial Lipopolysaccharide-Induced Damages. Neurochem. Int. 50, 219–228

    Not in our library10.1016/j.neuint.2006.08.006

  195. 195.

    Vincent A. J. Lau P. W. Roskams A. J. (2008 ). SPARC Is Expressed by Macroglia and Microglia in the Developing and Mature Nervous System. Dev. Dyn. 237, 1449–1462

    Not in our library10.1002/dvdy.21495

  196. 196.

    Vincent J. L. Marshall J. C. Namendys-Silva S. A. Francois B. Martin-Loeches I. Lipman J.. (2014 ). Assessment of the Worldwide Burden of Critical Illness: The Intensive Care Over Nations (ICON) Audit. Lancet Respir. Med. 2, 380–386

    Not in our library10.1016/s2213-2600(14)70061-x

  197. 197.

    Vutukuri R. Brunkhorst R. Kestner R. I. Hansen L. Bouzas N. F. Pfeilschifter J.. (2018 ). Alteration of Sphingolipid Metabolism as a Putative Mechanism Underlying LPS-Induced BBB Disruption. J. Neurochem. 144, 172–185

    Not in our library10.1111/jnc.14236

  198. 198.

    Vuuren M. J. V. Nell T. A. Carr J. A. Kell D. B. Pretorius E. (2020 ). Iron Dysregulation and Inflammagens Related to Oral and Gut Health Are Central to the Development of Parkinson’s Disease. Biomolecules 11, 30

    Not in our library10.3390/biom11010030

  199. 199.
  200. 200.

    Wang P. Hu Y. Yao D. Li Y. (2018 ). Omi/HtrA2 Regulates a Mitochondria-Dependent Apoptotic Pathway in a Murine Model of Septic Encephalopathy. Cell Physiol. Biochem. 49, 2163–2173

    Not in our library10.1159/000493819

  201. 201.

    Wang P. Wang W. Hu Y. Li Y. (2020 ). Prolonged Soluble Epoxide Hydrolase Reactivity in Brain Endothelial Cells Is Associated With Long Cognitive Deficits in Sepsis. Mol. Neurobiol. 57, 2846–2855

    Not in our library10.1007/s12035-020-01925-2

  202. 202.

    Wang H. Ward M. F. Sama A. E. (2014 ). Targeting HMGB1 in the Treatment of Sepsis. Expert Opin. Ther. Targets. 18, 257–268

    Not in our library10.1517/14728222.2014.863876

  203. 203.

    Wang K. Wu M. Xu J. Wu C. Zhang B. Wang G.. (2019 b). Effects of Dexmedetomidine on Perioperative Stress, Inflammation, and Immune Function: Systematic Review and Meta-Analysis. Br. J. Anaesth 123, 777–794

    Not in our library10.1016/j.bja.2019.07.027

  204. 204.

    Winkler L. Blasig R. Breitkreuz-Korff O. Berndt P. Dithmer S. Helms H. C.. (2021 ). Tight Junctions in the Blood-Brain Barrier Promote Edema Formation and Infarct Size in Stroke - Ambivalent Effects of Sealing Proteins. J. Cereb Blood Flow Metab. 41, 132–145

    Not in our library10.1177/0271678x20904687

  205. 205.

    Winkler E. A. Nishida Y. Sagare A. P. Rege S. V. Bell R. D. Perlmutter D.. (2015 ). GLUT1 Reductions Exacerbate Alzheimer’s Disease Vasculo-Neuronal Dysfunction and Degeneration. Nat. Neurosci. 18, 521–530

    Not in our library10.1038/nn.3966

  206. 206.

    Wu F. Chen X. Zhai L. Wang H. Sun M. Song C.. (2020 ). CXCR2 Antagonist Attenuates Neutrophil Transmigration Into Brain in a Murine Model of LPS Induced Neuroinflammation. Biochem. Biophys. Res. Commun. 529, 839–845

    Not in our library10.1016/j.bbrc.2020.05.124

  207. 207.

    Xu Z. Liu C. Wang R. Gao X. Hao C. Liu C. (2021 ). A Combination of Lycopene and Human Amniotic Epithelial Cells can Ameliorate Cognitive Deficits and Suppress Neuroinflammatory Signaling by Choroid Plexus in Alzheimer’s Disease Rat. J. Nutr. Biochem. 88, 108558

    Not in our library10.1016/j.jnutbio.2020.108558

  208. 208.

    Xu X. E. Liu L. Wang Y. C. Wang C. T. Zheng Q. Liu Q. X.. (2019 ). Caspase-1 Inhibitor Exerts Brain-Protective Effects Against Sepsis-Associated Encephalopathy and Cognitive Impairments in a Mouse Model of Sepsis. Brain Behav. Immun. 80, 859–870

    Not in our library10.1016/j.bbi.2019.05.038

  209. 209.
  210. 210.

    Yadollah O. Lee C. Jaleh B. David C. Saeed A. Mark G. (2003 ). Evaluation of the Immortalised Mouse Brain Capillary Endothelial Cell Line, B.End3, as an In Vitro Blood–Brain Barrier Model for Drug Uptake and Transport Studies. Brain Res. 990, 95–112

    Not in our library10.1016/s0006-8993(03)03443-7

  211. 211.

    Yamamoto M. Ramirez S. H. Sato S. Kiyota T. Cerny R. L. Kaibuchi K.. (2008 ). Phosphorylation of Claudin-5 and Occludin by Rho Kinase in Brain Endothelial Cells. Am. J. Pathol. 172, 521–533

    Not in our library10.2353/ajpath.2008.070076

  212. 212.

    Yamazaki Y. Shinohara M. Shinohara M. Yamazaki A. Murray M. E. Liesinger A. M.. (2019 ). Selective Loss of Cortical Endothelial Tight Junction Proteins During Alzheimer’s Disease Progression. Brain 142, 1077–1092

    Not in our library10.1093/brain/awz011

  213. 213.

    Yang Y. Estrada E. Y. Thompson J. F. Liu W. Rosenberg G. A. (2007 ). Matrix Metalloproteinase-Mediated Disruption of Tight Junction Proteins in Cerebral Vessels Is Reversed by Synthetic Matrix Metalloproteinase Inhibitor in Focal Ischemia in Rat. J. Cereb Blood Flow Metab. 27, 697–709

    Not in our library10.1038/sj.jcbfm.9600375

  214. 214.

    Yang T. Sun Y. Mao L. Zhang M. Li Q. Zhang L.. (2018 ). Brain Ischemic Preconditioning Protects Against Ischemic Injury and Preserves the Blood-Brain Barrier via Oxidative Signaling and Nrf2 Activation. Redox Biol. 17, 323–337

    Not in our library10.1016/j.redox.2018.05.001

  215. 215.

    Yan J. Mitra A. Hu J. Cutrera J. J. Xia X. Doetschman T.. (2016 ). Interleukin-30 (IL27p28) Alleviates Experimental Sepsis by Modulating Cytokine Profile in NKT Cells. J. Hepatol. 64, 1128–1136

    Not in our library10.1016/j.jhep.2015.12.020

  216. 216.

    Yao Y. Chen Z. L. Norris E. H. Strickland S. (2014 ). Astrocytic Laminin Regulates Pericyte Differentiation and Maintains Blood Brain Barrier Integrity. Nat. Commun. 5, 3413

    Not in our library10.1038/ncomms4413

  217. 217.

    Yeh C. T. Kao M. C. Chen C. H. Huang C. J. (2015 ). Platonin Preserves Blood-Brain Barrier Integrity in Septic Rats. Acta Anaesthesiol Taiwan. 53, 12–15

    Not in our library10.1016/j.aat.2015.02.001

  218. 218.

    Yi X. Xu C. Huang P. Zhang L. Qing T. Li J.. (2020 ). 1-Trifluoromethoxyphenyl-3-(1-Propionylpiperidin-4-Yl) Urea Protects the Blood-Brain Barrier Against Ischemic Injury by Upregulating Tight Junction Protein Expression, Mitigating Apoptosis and Inflammation In Vivo and In Vitro Model. Front. Pharmacol. 11, 1197

    Not in our library10.3389/fphar.2020.01197

  219. 219.

    Yue H. Xie K. Ji X. Xu B. Wang C. Shi P. (2020 ). Vascularized Neural Constructs for Ex-Vivo Reconstitution of Blood-Brain Barrier Function. Biomaterials 245, 119980

    Not in our library10.1016/j.biomaterials.2020.119980

  220. 220.

    Yu Y. Wang C. Zhang X. Zhu J. Wang L. Ji M.. (2020 ). Perfluorooctane Sulfonate Disrupts the Blood Brain Barrier Through the Crosstalk Between Endothelial Cells and Astrocytes in Mice. Environ. Pollut. 256, 113429

    Not in our library10.1016/j.envpol.2019.113429

  221. 221.

    Zengeler K. E. Lukens J. R. (2021 ). Innate Immunity at the Crossroads of Healthy Brain Maturation and Neurodevelopmental Disorders. Nat. Rev. Immunol. 21, 454–468

    Not in our library10.1038/s41577-020-00487-7

  222. 222.

    Zhang Y. Lu W. Wang Z. Zhang R. Xie Y. Guo S.. (2020 ). Reduced Neuronal cAMP in the Nucleus Accumbens Damages Blood-Brain Barrier Integrity and Promotes Stress Vulnerability. Biol. Psychiatry 87, 526–537

    Not in our library10.1016/j.biopsych.2019.09.027

  223. 223.

    Zhang M. Mao Y. Ramirez S. H. Tuma R. F. Chabrashvili T. (2010 ). Angiotensin II Induced Cerebral Microvascular Inflammation and Increased Blood-Brain Barrier Permeability via Oxidative Stress. Neuroscience 171, 852–858

    Not in our library10.1016/j.neuroscience.2010.09.029

  224. 224.

    Zhao L. An R. Yang Y. Yang X. Liu H. Yue L.. (2015 ). Melatonin Alleviates Brain Injury in Mice Subjected to Cecal Ligation and Puncture via Attenuating Inflammation, Apoptosis, and Oxidative Stress: The Role of SIRT1 Signaling. J. Pineal Res. 59, 230–239

    Not in our library10.1111/jpi.12254

  225. 225.

    Zhao Z. Hu J. Gao X. Liang H. Liu Z. (2014 ). Activation of AMPK Attenuates Lipopolysaccharide-Impaired Integrity and Function of Blood-Brain Barrier in Human Brain Microvascular Endothelial Cells. Exp. Mol. Pathol. 97, 386–392

    Not in our library10.1016/j.yexmp.2014.09.006

  226. 226.

    Zhao S. Zhang L. Lian G. Wang X. Zhang H. Yao X.. (2011 ). Sildenafil Attenuates LPS-Induced Pro-Inflammatory Responses Through Down-Regulation of Intracellular ROS-Related MAPK/NF-kappaB Signaling Pathways in N9 Microglia. Int. Immunopharmacol. 11, 468–474

    Not in our library10.1016/j.intimp.2010.12.017

  227. 227.

    Zheng Y. Wu Z. Yi F. Orange M. Yao M. Yang B.. (2018 ). By Activating Akt/eNOS Bilobalide B Inhibits Autophagy and Promotes Angiogenesis Following Focal Cerebral Ischemia Reperfusion. Cell Physiol. Biochem. 47, 604–616

    Not in our library10.1159/000490016

  228. 228.

    Zheng Q. Zhang Y. Zhao Z. Shen H. Zhao H. Zhao M. (2021 ). Isorhynchophylline Ameliorates Paraquat-Induced Acute Kidney Injury by Attenuating Oxidative Stress and Mitochondrial Damage via Regulating Toll-Interacting Expression. Toxicol. Appl. Pharmacol. 420, 115521

    Not in our library10.1016/j.taap.2021.115521

  229. 229.

    Zhou Y. Sonobe Y. Akahori T. Jin S. Kawanokuchi J. Noda M.. (2011 ). IL-9 Promotes Th17 Cell Migration Into the Central Nervous System via CC Chemokine Ligand-20 Produced by Astrocytes. J. Immunol. 186, 4415–4421

    Not in our library10.4049/jimmunol.1003307

  230. 230.

    Zhou T. Zhao L. Zhan R. He Q. Tong Y. Tian X.. (2014 ). Blood-Brain Barrier Dysfunction in Mice Induced by Lipopolysaccharide Is Attenuated by Dapsone. Biochem. Biophys. Res. Commun. 453, 419–424

    Not in our library10.1016/j.bbrc.2014.09.093

  231. 231.

    Ziesmann M. T. Marshall J. C. (2018 ). Multiple Organ Dysfunction: The Defining Syndrome of Sepsis. Surg. Infect. (Larchmt). 19, 184–190

    Not in our library10.1089/sur.2017.298

Cited by papers we hold 3

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.